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ABSTRACT 
We have developed an in vivo non-invasive gamma camera imaging system which uses 
125I to detect functional iodide metabolism in mammary tumors.  Iodide metabolism in 
these tumors is mediated by the sodium iodide symporter.  The quantity and pattern of 
radioiodide uptake varies between mammary tumors.  We have previously shown that 
localization of NIS protein expression reflects the radioiodide uptake in gamma camera 
images.  In this study, we investigate whether expression levels of NIS mRNA in 
mammary tumors correlate with 125I uptake pattern shown in gamma camera images.  Our 
hypothesis is that NIS function in mammary tumors and non-tumor mammary glands is 
regulated primarily at the transcriptional level.  To test this hypothesis, we quantified NIS 
mRNA levels using TaqMan real-time RT-PCR, and constructed a cRNA standard curve 
for quantification.  The ratio of NIS to the housekeeping gene β-actin was compared to 
the intensity and pattern of mammary tumor radioiodide uptake as imaged by the gamma 
camera.  In MMTV tumors, our results suggest that NIS is under both transcriptional and 
post-transcriptional control in this model for breast cancer.  In separate tumors, we 
observed both positive correlation and no correlation between NIS mRNA level and 
radioiodide uptake.  We also found that NIS mRNA levels were increased in non-
palpable tumors in correlation with increases in radioiodide uptake, suggesting that an 
upregulation of NIS mRNA occurs in early tumor development.   
 
 1 
INTRODUCTION 
Overview 
 While the number of deaths resulting from breast cancer has dropped gradually 
over the past 15 years, it remains the most prevalent cancer in females (Jemal, 2007).  In 
2007, the number of new cases in the United States reached 178,480.  Despite the decline 
in the breast cancer death rate, more than 40,000 women died from this form of cancer in 
the past year.   
Early detection and diagnosis of breast cancer offers the best strategy to improve 
the odds of curing the disease (Benard, 2005).  Imaging systems such as mammography 
and magnetic resonance imaging (MRI) are currently used for breast cancer screening 
and early detection.  While these technologies create images displaying anatomical 
features of the breast, they lack the capacity to convey any functional information 
(Lyons, 2005).  With the implementation of strategies such as positron emission 
tomography (PET) and gamma camera imaging, functional information about tumor 
physiology could be gathered (Benard, 2005).  While PET conveys information on cell 
metabolism, effective diagnosis of breast cancer relies upon information regarding gene 
expression patterns and molecular alterations that cannot be obtained without targeting a 
breast cancer-specific ligand.  One promising methodology for obtaining molecular 
images is using gamma camera imaging and radioiodide.  
Gamma camera imaging has been employed previously for breast cancer imaging 
and detection (Schillaci, 2006; Brem, 2007).  Imaging using a gamma camera measures 
low energy gamma rays for in vivo detection of iodinated compounds that display 
functional information of mammary tumor activity.  We are currently using a mouse 
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mammary tumor virus (MMTV)-infected mouse model to develop this system for early 
detection of tumor development and to investigate the relationship between 
heterogeneous uptake of 125I and mammary tumor progression.  The gamma camera 
developed by Bradley et al. (2006) has resolution which is sufficient to detect the 
presence of non-palpable tumors.  Additionally, as tumors develop distinct patterns of 
radioiodide uptake have been observed.  Ultimately, we aim to relate this heterogeneity 
of iodide uptake patterns to differences in gene and protein expression within mammary 
tumors. 
 Iodide uptake in mammary tumors relies on expression of the sodium iodide 
symporter (NIS), a transmembrane protein that cotransports sodium and iodide into cells 
(Tazebay, 2000).  This study investigates how levels of NIS mRNA levels correlate to 
both the total amount and pattern of radioiodide uptake in MMTV-induced mammary 
tumors.  To provide the necessary background for the presentation of this study, the 
remainder of this chapter will discuss (1) the biology of MMTV-induced mammary 
cancer, (2) the modalities used in breast cancer imaging, genes currently used as markers 
for breast cancer development, and (3) the current usage of molecular imaging in breast 
cancer detection and diagnosis.  
 
Mouse Mammary Tumor Virus – A Mouse Model for Breast Cancer 
 The mouse mammary tumor virus (MMTV) is a retrovirus, inserting its DNA into 
the host genome and insertionally activating host proto-oncogenes (Cardiff, 2007).  
MMTV exists in both exogenous and endogenous forms (Golovkina, 1997).  Exogenous, 
or milk-borne, MMTV is transmitted from infected mice to newborns through the breast 
 3 
milk during nursing.  An exogenous MMTV inserts its provirus into the host genome and 
leads to activation of downstream oncogenes.  Nearly all laboratory mice contain 
endogenous MMTVs within their genomes.  These endogenous MMTVs are often 
inactive due to regulatory or coding region mutations.  Proviral expression of inserted 
exogenous MMTV or functional endogenous MMTV is transcriptionally regulated by a 
long terminal repeat (LTR) sequence.  The MMTV-LTR contains hormone response 
elements within its sequence that drive MMTV expression, driving downstream 
activation of host oncogenes (Cardiff, 2007).  The oncogenes which can be activated by 
insertion of MMTV include ras, myc, erbB, Fos, and myb.  A mouse will develop 
mammary tumors upon activation of the MMTV-LTR in mammary gland tissue and 
downstream activation of host oncogenes. 
The MMTV mouse is a widely used model of breast cancer because of the 
similarity between mouse and human mammary glands and the ability for MMTV mice 
to spontaneously develop tumors (Cardiff, 1999).  MMTV-infected mouse models have 
been used in the description of the natural history of neoplasia, oncogenic viruses, 
endocrinology, and neoplastic progression (Cardiff, 2007).  The model has also been 
recently used in the study of signaling in breast cancer, including NIS signaling (Politi, 
2004;  Knostman, 2004)  We have used this proven model in the development of an 
imaging system that aims to use the molecular characteristics of mammary tumors to 
further understanding of early diagnosis of breast cancer. 
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Breast Cancer Imaging 
  Because early diagnosis is an important step to ensure the most effective 
treatment of breast cancer, a strong focus has been placed on imaging technologies for 
screening and diagnosis the disease (Benard, 2005).  Imaging strategies currently 
implemented for widespread clinical use, including mammography and MRI have been 
useful in breast cancer diagnosis but additional techniques can significantly improve 
diagnostic imaging.  While the anatomical images created by mammography and MRI 
are useful, functional images through PET and gamma camera imaging provide more 
specific information (Benard 2005; Quon, 2005).  Gamma camera imaging additionally 
offers the potential for molecular imaging using ligands specific to breast cancer 
(Torigian, 2007).  Using a combination of these technologies will greatly improve the 
current ability for early diagnosis of breast caner.  
     
Mammography 
 Mammography has been used as preferred method of screening for breast cancer 
for over 40 years (Elmore, 2005).  This imaging modality uses ionizing radiation in the 
form of X-rays to record the variations in density of the tissue through which the 
radiation passes (Esserman, 2002).  This anatomical image can display dense masses that 
have the potential to be abnormal tissue or calcifications that signify the development of 
breast cancer.  However, because mammography measures only the density of breast 
tissue, the image does not contain any functional information about the breast.  Because 
of its lack of specificity, the mammogram has difficulty detecting abnormalities in dense 
breasts, and leads to false positive diagnoses.      
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Magnetic Resonance Imaging 
 MRI provides an imaging modality with higher sensitivity and conveys more 
functional information than mammography, but does not provide any molecular or 
metabolic information (Esserman, 2002; Lyons 2005).  The signal for MRI is generated 
by measuring protons in H2O molecules using radiowaves (Esserman, 2002).  An image 
is produced by visualization of the differences in H2O content in tissues, distinguishing 
between tissue types.  In breast cancer MRI, a contrast agent consisting of a paramagnetic 
cation probe often containing gadolinium is necessary to enhance the signal where it 
accumulates (Esserman, 2002; Lyons 2005).   
 MRI creates anatomical images, with a resolution of approximately 25 µm 
(Lyons, 2005).  Highly vascularized dense tissue images particularly well with MRI.  
However, a significant limitation to the use of MRI for gathering functional information 
about a mammary tumor exists in its inability to provide any specific molecular 
information (Hylton 2005).  Because of its reliance on measuring only relative  water 
content, MRI lacks molecular specificity, and therefore possesses the potential to give 
high percentages of false positive diagnoses (Wright 2005).  The high cost of MRI also 
contributes to its limitations in widespread clinical use.   
 While MRI in clinical use is limited to anatomical imaging, its use in noninvasive 
in vivo mouse imaging is expanding to include functional information about tissue 
physiology (Lyons, 2005).  While traditional MRI relies on non-targeted probes, new 
advances utilize probes which can localize specifically to tumor cells.  Examples include 
using cross-linked iron oxide to detect overexpression of the MUC1 promoter in tumors 
and using an iron oxide-transferrin chelate to detect overexpression of the transferrin 
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receptor.  These examples display the potential for an improved level of specificity and 
ability to image tumor function in the use of MRI. 
  
Positron Emission Tomography 
 Positron emission tomography detects the annihilation of photons from positron-
emitting radioisotopes such as 15O, 13N, 11C, and 18F (Benard, 2005).  PET imaging with 
[18F] fluorodeoxyglucose (18F-FDG) is used commonly in cancer prognosis in many 
cancer centers across the United States (Benard, 2005; Quon, 2005).  18F-FDG detects 
cancer through its incorporation into cells at a rate proportional to that of glucose 
metabolism (Nahmias, 2002; Quon, 2005).  The radioisotope follows the glycolysis 
pathway and is phosphorylated by hexokinase (Benard, 2005).  This phosphorylated 18F-
FDG cannot be metabolized further by the cell and is trapped at this stage of the pathway.  
In cancer, where glycolytic rate is increased compared to normal tissue, the 
phosphorylated 18F-FDG trapped in these cells is significantly greater than the 
surrounding tissues, allowing detection using PET based on the increased positron 
emission in these cancer tissues (Quon, 2005).   
 The benefit of PET imaging over mammography or MRI is found in its capability 
to acquire functional information of glucose metabolism within a tumor (Quon, 2005).  
While mammography and MRI can detect abnormalities in breast tissue, PET can 
differentiate cancerous tissue from normal tissue by tracing functional rather than 
morphological abnormalities.  Considering this information, PET imaging demonstrates 
potential for use in diagnosis, staging, restaging, and monitoring the treatment of breast 
cancer (Schoder, 2007).   
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However, PET imaging only demonstrates changes glucose metabolism, not gene 
expression information that will lead to diagnosis and prognosis of the type of breast 
cancer (Benard, 2005).  False negatives result both from the poor capability of 18F-FDG 
PET to image noninvasive breast cancer and the low detection rate in small tumors (0.4-
1.5 cm) (Quon, 2005).  False positives are detected by PET in benign inflammations and 
fibroadenomas of the breast.  While PET imaging using 18F-FDG signifies an 
improvement in terms of the ability to functionally image breast cancer, its limitations in 
specificity and sensitivity suggest the need for an additional imaging technology. 
 
Gamma Camera Imaging Using the Sodium Iodide Symporter 
 Gamma ray emitting radioisotopes such as 123I, 125I, and 131I injected into a subject 
can be detected using gamma cameras to image molecular events as the radioiodide is 
taken up by tissues that express the sodium iodide symporter (Schipper, 2007).  This 
technology provides the ability for repeatable, non-invasive imaging which monitors 
functional activity through radioiodide uptake (Dingli, 2003).   
 Gamma camera imaging using radioiodide provides many significant advantages 
over 18F-FDG PET scans.  Gamma camera technology is more available to hospitals than 
PET scanners (Dingli, 2003).  In addition, 125I and other radioactive iodide isotopes are 
readily commercially available at a low cost, while PET radiotracers require sophisticated 
onsite radiochemistry to produce (Dingli, 2003; Weisenberger, 2003).  The long half-life 
(60 days) of 125I also allows tracking of biological processes in animals, which cannot be 
accomplished using short half-life radiotracers such as 18F used in PET.  Also, the use of 
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radioiodide is already approved for medical use by the FDA, easing the transition to use 
in clinical practice (Dingli, 2003).    
The gamma camera for small animal imaging developed by Bradley et al. (2006) 
improves on the current resolution capabilities of gamma cameras used for cancer 
imaging.  Currently available gamma cameras can produce images with a range of 5-10 
mm resolution (Dingli, 2003).  The compact gamma camera for biological imaging 
described in Bradley et al. (2006) has the capacity to produce images with a resolution of 
2.5 mm using the radioisotope 125I.  With high resolution, non-invasive functional 
imaging at low cost, this gamma camera possesses the capacity for early detection of 
breast cancer by monitoring radioiodide uptake through NIS.   
 
Breast Cancer Markers and Reporter Genes 
 With its ability to develop in vivo high resolution images, our system for gamma 
camera imaging has the potential to use radiolabeled ligands that reveal molecular and 
functional information about a tumor.  Many genes are overexpressed in breast cancer, so 
determining such overexpression can offer valuable information about the phenotype of 
the cancer, which has implications on treatment strategy and probability of recurrence 
and metastasis (Kapp, 2006).  The following discusses some particularly important 
ligands which are overexpressed in breast cancer cells, and provide functional 
information of tumor activity. 
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Estrogen Receptor 
 The estrogen receptor alpha (ERα) is coded for by the Esr1 gene, and is expressed 
in approximately 75% of invasive breast cancers (Fowler, 2007; Allred, 2004).  ERα is a 
nuclear receptor that binds the sex steroid hormone, estrogen and directly activates an 
estrogen responsive element on DNA (Ikeda, 2004).  Esr1 and ERα overexpression has 
been demonstrated in benign breast lesions, carcinomas in situ, and invasive breast 
carcinomas (Fowler, 2007).  In each of these samples, ERα expression contributed to 
tumorigenesis and cancer cell proliferation.  Mammary tumors that are well-
differentiated, responsive to endocrine therapy, and have a generally favorable prognosis 
are correlated with ERα expression.  Because of its prognostic value, determination of 
ERα expression provides valuable information about tumor progression and 
development.  This information would be useful in our radioiodide imaging system. 
 
Amphiregulin 
 Amphiregulin (AREG) is an autocrine growth factor and a member of the 
epidermal growth factor family of proteins that activates the epidermal growth factor 
receptor (EGFR) (Normanno, 1994; Ma, 1999; Ciarloni, 2006).  AREG expression is 
documented in normal and malignant epithelial tissues and has the potential to either 
stimulate or inhibit cell growth depending on the presence of other growth factors 
(Normanno, 1994).  In mammary tumorigenesis, AREG has been implicated as a major 
element in estrogen-induced breast cancer cell proliferation (Ciarloni, 2006).  In addition 
to its role in cell proliferation, AREG has also been shown to play a role in endothelial-
mesenchymal transition (EMT) in human kidney cells as well as in tumor angiogenesis 
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(Lee, 2007; Ma, 1999).  Because of the above factors and its enhancement of 
tumorigenicity in breast cancer cell lines, the use of AREG as a therapeutic target and 
prognostic indicator is promising.  As a prognostic indicator of tumor progression and 
estrogen-induced tumor cell proliferation, the use of 125I-tagged AREG as a marker for 
breast cancer development is promising for our small animal gamma camera detector 
system. 
  
Sodium Iodide Symporter 
 The sodium iodide symporter (NIS) is a plasma membrane glycoprotein with an 
extracellular amino terminus and intracellular carboxyl terminus, and contains 13 
putative transmembrane domains (Smanik, 1997; Levy, 1998).  The gene that encodes 
NIS consists of 15 exons separated by 14 introns.  Three potential N-linked glycosylation 
sites exist, one on the seventh extramembrane loop and two on the thirteenth 
extramembrane loop.  NIS is endogenously expressed in thyroid, gastrointestinal tract,  
salivary gland, and lactating mammary gland where it allows the cellular uptake of iodide 
(Dai, 1996; Tazebay, 2000).  Two sodium ions and one iodide ion are cotransported 
across the cell membrane through NIS (Carrasco, 1993). The transmembrane sodium 
gradient generated by the sodium/potassium ATPase acts as a driving force for iodide 
uptake and can be inhibited by perchlorate.  According to Tazebay et al. (2000), 
mammary gland NIS and gastric NIS, yield the same peptide map as thyroid NIS and the 
clones of human cDNAs of thyroid, mammary gland, and gastric NIS are in agreement 
(Spitzweg, 1998).  Mouse NIS was cloned in 2001, and found to have 95% identity with 
rat NIS and 81% identity with human NIS (Perron, 2001).  Differences between human 
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and mouse NIS efficiency of iodide transport have been documented in transfected 
human embryonic kidney 293 cells (Dayem, 2008).  Localization studies of human NIS 
compared with mouse NIS additionally found that mouse protein was located 
predominately on the cell membrane, while approximately 40% of cells transfected with 
human NIS demonstrated intracellular protein localization.    
 Tazebay et al. (2000) established that 125I was concentrated in lactating mammary 
gland in rats, but not in surrounding skeletal muscle of the same rat or in mammary 
glands form non-lactating rats.  Using antibody for rat thyroid NIS, a single band of 75-
kDa was detected in immunoblot analysis of rat lactating mammary gland.  Immunoblot 
analysis also showed that NIS expression in rat mammary gland varies in different 
physiological stages (Cho, 2000; Tazebay, 2000).  Mammary gland NIS protein 
expression begins in late pregnancy, continues through lactation, and is abolished 48h 
after suckling ceases.  With re-initiation of suckling, NIS expression levels increase.  
Immunohistochemical staining demonstrated that NIS is located on the basolateral 
membrane of alveolar epithelial cells, which are much more developed in the lactating 
mammary gland than in glands of virgin individuals.  RT-PCR analyses on rat mammary 
tissues produced positive results for non-lactating as well as lactating tissues, indicating 
that while protein is not present at detectable levels, NIS mRNA is constitutively 
expressed (Tazebay, 2000; Spitzweg, 1998).  Perron et al. (2001) used semi-quantitative 
RT-PCR studies of mouse NIS to show that lactating mammary gland expressed 
significantly more NIS mRNA than virgin, pregnant, or involuting mouse mammary 
glands,   
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Immunoblot analysis revealed that hormonal regulation of rat NIS protein 
expression is mediated by prolactin, oxytocin, and β-estradiol (Cho, 2000; Tazebay, 
2000), but the pathways are not well understood (Riesco-Eizaguirre, 2006).  Oxytocin 
alone, but not in combination with prolactin, induced NIS expression (Tazebay, 2000).  
This finding suggests that NIS can be expressed in the mammary gland independently of 
gestation- and lactation-related changes.    
 
NIS in Breast Cancer 
 NIS expression and function in breast cancer was first documented by Tazebay et 
al. (2000).  Functional expression of NIS was demonstrated in mammary tumors of two 
female transgenic mice, one with an activated Ras oncogene and the other overexpressing 
the Neu oncogene (Tazebay, 2000).   Both genes were under transcriptional control of an 
MMTV promoter/enhancer.  Using scintigraphic imaging, 99mTcO4 accumulation was 
reported in mammary gland adenocarcinomas of both mouse strains.  Immunoblot 
analysis showed NIS protein expression in these mammary tumors (Tazebay, 2000).  
Contralateral nontumoral mammary glands showed no NIS expression upon 
immunoblotting.  Functional NIS expression was also demonstrated through 125I and 131I 
uptake studies in human primary breast tumors (Moon, 2001).  Expression of NIS mRNA 
in human breast carcinomas was demonstrated by RT-PCR (Kilbane, 2000).  MMTV-
PyVT transgenic mice with spontaneously developing tumors were also shown to have 
NIS mRNA expression by RT-PCR (Kogai, 2004).  The localization of NIS protein in 
breast cancer differed from its exclusive expression on the basolateral surface of alveolar 
cells in lactating mammary glands.  When a group of seven transgenic mouse models 
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showed positive immunohistochemical staining for NIS in mammary tumors, some 
showed staining on only the plasma membrane, while others expressed NIS 
intracellularly (Knostman, 2004).  In situ staining by Tazebay et al. (2000) also 
demonstrated both plasma membrane and intracellular staining in malignant breast cells.   
 Sodium iodide symporter expression studies in human breast cancer tissue have 
shown that NIS is frequently expressed in mammary carcinomas, suggesting that the NIS 
could be used as a marker for this type of breast cancer.  The high prevalence of NIS 
expression in mammary carcinomas (80%) and its absence in normal tissue compared 
with the 33% prevalence of a current breast cancer marker, Her2/neu, suggests that NIS 
expression and radioiodide uptake may be a more effective breast cancer marker in some 
cases than current methods (Dohan, 2003a).  Additional immunohistochemical studies 
have shown that a significant percentage of mammary carcinomas are positive for NIS.  
IHC analysis of 371 human breast cancer cases showed positive in situ staining for NIS 
in 88% of ductal carcinomas and 76% of invasive carcinomas while 87% of normal 
breast samples were negative (Wapnir, 2003).  In a study of human breast tissues, 87% of 
23 invasive carcinomas and 83% of six ductal carcinomas in situ expressed NIS 
compared with 23% of noncancerous samples in the vicinity of the tumors (Tazebay, 
2000).  While these studies suggest a strong correlation between breast cancer 
development and NIS expression, Moon et al. (2001) found a weaker correlation between 
correlation between functional NIS shown by 99mTcO4 accumulation and NIS mRNA 
expression.  The relationship was tested in 25 patients with four out of 25 mRNA 
expressing tumors possessing functional uptake.  Although Moon’s percentage of 
functional NIS is significantly lower than NIS protein expression, a review by Dohan and 
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Carrasco suggests that these results are still highly meaningful because iodide uptake in 
the thyroid was not blocked in these patients (Dohan, 2003b).  They suggest that a larger 
proportion of radioiodide uptake could occur in the mammary gland tumors or metastases 
if thyroid radioiodide uptake was suppressed by T3 (Wapnir, 2004).   
 
Relationship between expression of NIS and the Estrogen Receptor 
 In order to understand more specifically the characteristics of cancers that express 
NIS, the estrogen receptor (ERα) and associated genes have been investigated in breast 
cancer cell lines and in human breast cancer tissue samples and compared with the 
presence of NIS.  According to Kogai et al. 2000, 125I uptake, as well as NIS expression, 
in MCF-7 cells is present, but small at baseline.  Uptake of 125I did not occur in ER-
negative MDA-MB-231 breast cancer cells or in MCF-12A normal breast cells.  A more 
comprehensive study of breast cancer cell lines by Alotaibi in 2006 showed by RT-PCR 
that the ER+ cell lines BT-474, T-47D, and MCF-7 expressed NIS, as well as the ER- 
cell line, BT-20.  Only ER positive cell lines were capable of increased NIS expression 
following trans-retinoic acid (tRA) treatment.   
 In human breast cancer samples, both ER-positive and ER-negative tissues show 
NIS expression in real-time RT-PCR (Tanosaki, 2003) and immunohistochemistry 
(Wapnir, 2004) analysis.  Twenty-two human breast cancer samples, among which eleven 
were ER-positive, were compared with MCF-7 human breast cancer cells.  Only three of 
these tissue samples showed NIS activity above that of MCF-7.  Of these, two were ER-
positive and one was ER-negative.  Wapnir et al. (2004) examined 27 patients with 
metastatic breast cancer who underwent 99mTcO4 or I-123 scans, and correlated results 
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with IHC findings in 23 of these cases.  Of the 23 cases studied, eight stained positive for 
NIS (34.8%).  Three of the nine metastatic samples and five of the 14 primary tissue 
samples that were collected stained positive for NIS.  Seven of the eight positive NIS 
tissues were ER-negative, indicating that NIS is expressed in both ER-positive and ER-
negative tissues despite many ER-negative breast cancer cell lines lacking NIS 
expression.  These findings suggest that further studies of NIS expression in ER-positive 
and ER-negative breast cancer tissues are required to more completely understand the 
relationship between ER expression and NIS-regulated iodide uptake in breast cancer. 
 
Molecular Imaging of Breast Cancer 
 Molecular imaging in breast cancer utilizes target molecules, such as those 
mentioned above, with specific roles in the development of the disease.  This type of 
imaging offers more specific targets than the structural/anatomical imaging techniques 
such as mammography and MRI (Torigian, 2007).  These molecular targets can provide 
information to assist in prognosis or treatment of the cancer, which structural imaging 
cannot provide without a biopsy.  Molecular imaging with specific cellular targets can 
measure specific cellular events such as proliferation and apoptosis which surpasses 
imaging modalities such as FDG-PET (Mankoff, 2004).  This analysis of tumor activity 
examines specific events within the tumor, rather than only providing information on 
how the tumor metabolizes glucose.  Overall, the potential for molecular imaging to offer 
a quantitative measurement of a target, while simultaneously having the capacity to 
identify resistance factors for treatment and measure treatment response reveals the 
promise of this imaging strategy for future diagnosis and treatment of breast cancer.  
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Molecular Imaging Strategies in Breast Cancer 
 Current strategies in molecular imaging which employ PET imaging include cell 
proliferation, apoptosis, and estrogen receptor imaging (Mankoff, 2004; Torigian, 2007).  
Cell proliferation imaging measures the uptake of nucleosides incorporated into nucleic 
acid synthesis using the nucleoside analogue 3’-deoxy-3’-18F-fluorothymidine (FLT).  
This tracer, similar to 18F-FDG becomes phosphorylated and cannot be metabolized 
further, allowing for imaging using PET.  While FLT is specific to cellular-proliferation 
activity, its sensitivity is less than that of FDG-PET for the detection of cancer.  This 
suggests that the current system using FLT is extremely useful in monitoring anti-
proliferation treatment, but lacks the sensitivity to be used as a cancer detection system.   
Imaging of apoptosis within tumors can be achieved using a either a ligand 
labeled with 125I to be detected with SPECT or 18F to be detected with PET radioisotope 
that can be detected using SPECT or PET imaging.  Annexin V can be labeled and 
imaged when it binds to phosphatidylserin (PS).  PS moves the surface of the cell 
membrane when apoptosis occurs, at which point Annexin V binds and can be detected 
using radionuclide imaging Torigian, 2007). 
As mentioned above, the estrogen receptor is an important target for breast cancer 
therapy, and detecting this molecule in vivo is particularly useful because it is screened 
for often in biopsies.  Using the estrogen analogue 16α-18F-fluoroestradiol-17β (FES) 
with PET, the activity of the estrogen receptor can be non-invasively imaged in vivo 
(Mankoff, 2004).  It has also been demonstrated that this FES-PET imaging can be 
accurately quantified, providing information on the level of ER expression.  FES-PET 
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provides the potential to monitor and prescribe treatment protocols based on the presence 
of the ER as assessed in vivo.   
 
NIS as a Reporter Gene 
NIS has potential as a reporter gene for breast cancer as well as a therapeutic 
gene.  The ability of this transmembrane protein to cotransport sodium with a multitude 
of different anions contributes to its versatility and usefulness.  In addition to I-, NIS can 
also transport ClO3-, SCN-, SeCN-, NO3-, Br-, TcO4-, RhO4-, and 211At into cells (Dingli, 
2003).  In Dingli et al. (2003), NIS in the form of a replication competent measles virus 
(MV-NIS) was used to trace 123I uptake in myeloma xenograft tumors in mice.  These 
tumors were imaged after 17 days to allow for MV-NIS proliferation with a gamma 
camera, and displayed prominent radioiodide uptake in the regions of the myeloma 
tumors.  Exogenously introduced NIS was successfully demonstrated as a breast cancer 
reporter gene by Schipper et al. (2007) and Dwyer et al. (2005).  Schipper’s group 
measured radioiodide uptake in mouse neuroendocrine xenograft tumors with stably 
transfected NIS.  These mice were then imaged with gamma camera and SPECT imaging 
to detect regions of radioiodide uptake.  Dwyer performed a similar analysis using a NIS 
expression driven by a MUC-1 promoter in breast cancer xenografts.     
In studies of ER-positive breast cancer cell lines such as MCF-7, NIS induction 
through trans- or 9-cis- retinoic acid treatments have been shown to increase mRNA and 
protein expression levels substantially (Kogai, 2000; Kogai, 2004; Tanosaki, 2003).  
Kogai showed that tRA stimulation of MCF-7 cells led to an increase of NIS mRNA 
expression using Northern blot analysis and an increase in protein expression by western 
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blotting.  The same studies on ER-negative MDA-MB-231 cells expressed low levels of 
NIS protein initially, which increased very slightly upon tRA treatment.  MCF-7 
xenograft tumors grown in female SCID mice and treated with tRA show 125I uptake in 
vivo, while no uptake occurs without tRA treatment.  RT-PCR and western blots showed 
increased levels of mRNA expression and protein expression, respectively, upon tRA 
treatment in MCF-7 xenograft tumors.    
  
Potential of Molecular Imaging 
 Molecule-specific non-invasive in vivo imaging presents an opportunity to obtain 
quantitative information regarding physiological processes that cannot be achieved with 
strictly anatomical imaging technologies.  Continued study of molecular imaging ligands 
and advances in imaging technology to improve image resolution will likely impact the 
ability to detect tumors early in development, monitor therapy, and develop a prognosis 
using non-invasive techniques (Torigian, 2007).  The overall goal of the field of 
molecular imaging is to correlate imaging with molecular mechanisms, eventually 
gaining the capacity to image at the molecular level and to produce an image predictive 
of a molecular signature.  Through our study of NIS in breast cancer, we aim to combine 
gamma camera imaging with molecular biology for the early detection of mammary 
tumors and to determine if radioiodide uptake correlates with NIS protein and mRNA 
expression.  We will then determine if these images possess predictive value for breast 
cancer diagnosis or prognosis.   
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Hypothesis and Predictions 
 In our current experimental approach, we are using gamma camera imaging of the 
early development of mammary tumors by measuring and visualizing radioiodide uptake 
in MMTV-induced mammary tumors via endogenous expression of NIS.  We are 
examining if NIS mRNA levels correlate with the intensity and pattern of radioiodide 
uptake in mammary tumors.  Our working hypothesis is that NIS expression in mammary 
tumors is regulated primarily at the transcriptional level.  From this hypothesis, we 
predict that tumors (or regions of tumors) with higher levels of iodide uptake, as revealed 
by the gamma camera image, will have correspondingly higher levels of NIS mRNA.   
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MATERIALS AND METHODS 
Animals and Gamma Camera 125I  Imaging 
 The mouse model used in this study was from the strain C3H (Jackson 
Laboratories), and contained an endogenous MMTV.  This model spontaneously 
developed tumors specific to the mammary glands.  We used C57BL/J6 mice in studies 
of radioiodide uptake in lactating, multiparous, and nulliparous mice for comparison with 
data from MMTV mice.  All mouse studies were carried out using protocols approved by 
the College of William & Mary animal committee. 
 Mouse imaging was performed following an injection of 14 µCi of Na125I in 0.10 
ml 0.9% saline into the femoral biceps of the left rear leg as described in Bradley et al. 
(2006).  The gamma camera for small animal imaging was described previously 
(Weisenberger, 2003; Bradley, 2006; Hammond, 2007) and will be briefly described 
here.  The detector consists of a Hamamatsu R3292 position-sensitive photomultiplier 
tube and is air coupled to a pixilated array of CsI scintillating crystals.  A 3.0 mm thick 
CuBe parallel hole collimator with 0.2 mm square holes separated by 0.11 mm septal 
walls was placed in contact with the scintillator.  The system provides an effective special 
resolution of 2.5 mm (FWHM) on contact with the detector surface.  Data collection 
performed as described in Hammond et al. (2007) with additional analysis of region of 
interest (ROI) data.  Data were collected in five minute time-cuts over a period of 60 
minutes using KMAX data acquisition software on a Macintosh G4 system to record the 
time and energy of each photon emitted.  These data were examined by ROI analysis by 
defining regions incorporating tumors and mammary glands without the inclusion of 
surrounding tissues that also showed radioiodide uptake.  An IDL-based program was 
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used to create an array of the total number of counts per pixel in each ROI, allowing the 
size of the tumor to be defined as well as displaying its pattern of radioiodide uptake. 
 
RNA Extraction and DNaseI Treatment 
Total RNA was isolated from frozen tissues by RNeasy maxi kits following the 
manufacturer’s protocols (QIAGEN, Valencia, CA)  with tissue homogenization 
performed using a Tissue Tearor rotor homogenizer (Biospec Products, Inc., Bartlesville, 
OK).  To assess RNA quality, 10 µl of total RNA from each extraction was added to 2 µl 
6X dye components and was separated on 1.2% agarose gel stained with ethidium 
bromide. RNA samples were only used for further analyses if two distinct bands 
appeared, signifying intact 28S and 18S rRNA.   
Following total RNA elution, DNA-free DNaseI treatment was applied to all 
samples of extracted total RNA (Ambion, Foster City, CA).  For each DNaseI treatment, 
10 µg of total RNA was combined with 1 µl of DNaseI at a concentration of 2 U/µl 
according to manufacturer protocol for normal treatment.  Concentration of RNA was 
determined prior to and following DNaseI treatment using a NanoDrop Spectrometer 
with NanoDrop 3.5.2 software. DNaseI treated RNA was stored at -80°C. 
 
Reverse Transcriptase PCR 
cDNA Synthesis 
 DNaseI-treated RNA samples were reverse-transcribed using a Bio-Rad iScript 
cDNA Synthesis kit (Hercules, CA) following the manufacturer’s protocol with the 
following modifications.  For each reaction, 1 µg of RNA template was added to the 
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reverse-transcription reaction and incubated in a Bio-Rad iCycler for 5 minutes at 25°C, 
60 minutes at 42°C, and 5 minutes at 85°C.  A reaction lacking reverse transcriptase was 
also performed for each RNA sample reverse-transcribed to be used as a negative control 
in RT-PCR.  The cDNA products were stored at -20°C until further use. 
 
Primer Design and Handling for non-quantitiative RT-PCR 
Intron-spanning sense and anti-sense primers were designed using Primer3 
software (http://frodo.wi.mit.edu/).  NCBI sequence information was entered into 
Primer3 software and primers were developed using the following parameters.  Primer 
size between 18 and 27 base pairs was required, with 20 base pairs as the optimal 
molecular size, which is long enough to ensure sequence specificity while short enough 
to preventing mismatch pairing.  This allows for high efficiency in annealing to the 
template.  Primer melting temperature (Tm) and GC content were specified within the 
ranges of 53-60°C and 20-80%, respectively.  Upon entering these specifications into 
Primer3 software, typically 2-4 sense/anti-sense primer combinations for each gene 
resulted.  In the case of multiple primer set results, the first criteria for selection was 
whether the region of amplification crossed an exon-intron barrier.  Only primer sets that 
crossed exon-intron barriers were used in RT-PCR.  Exon-intron barriers were 
determined using NCBI sequence information.  Primer sequences were then entered into 
an NCBI BLAST search (http://www.ncbi.nlm.nih.gov/BLAST/) to confirm high 
specificity for the gene of interest.  (Table 1) If multiple primer sets matched these 
criteria, those with the lowest sequence identity with related genes expressed in Mus 
musculus were chosen.   
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Primers were manufactured by Integrated DNA Technologies (Coralville, IA) and 
shipped in lyophilized form.  These were brought up in 1X Tris-EDTA (TE) to create 1 
mM stocks and diluted to 100 µM and 10 µM stocks with nuclease-free H2O.  Primer 
1mM stocks were stored at -80°C and dilutions were stored at -20°C.   
 
Polymerase Chain Reaction 
PCR was performed using Taq polymerase (New England Biolabs, Beverly, MA) 
and assembled and cycled under the following conditions.  For each 50 µl reaction, 5 µl 
of 10X Thermopol buffer (New England Biolabs) which contains 2 mM of Mg2+ in the 
1X dilution, 1 µl 40 mM dNTP mix (Promega, San Luis Obispo, CA) and nuclease-free 
H2O were assembled in a master mix and an aliquot was transferred to 0.2 ml PCR tubes.  
To each tube, 2.5 µl of the 10 µM dilution of both forward and reverse primers to a 
concentration of 500 nM and 1 µl cDNA template were added.  The samples were then 
placed in a Bio-Rad iCycler and incubated at 94°C for 5 minutes.  Following this hot 
start, 0.25 µl Taq polymerase (New England Biolabs) was added to each reaction.  The 
iCylcer protocol then performed 40 cycles of denaturation at 94°C for 30 seconds, 
annealing at 64°C for 1 minute, and extension at 72°C for 2 minutes, followed by a final 
extension at 72°C for 7 min.  Negative controls lacking reverse-transcriptase in cDNA 
synthesis were performed for each PCR.   
 PCR products were analyzed by separation based on molecular size on a 1.2% 
agarose gel and stained with ethidium bromide.  Gels were visualized under UV light 
using the Alpha Innotech (San Leandro, CA) FluorChem HD2 detection system. 
 
 24 
TaqMan Quantitative Real-time PCR 
Primer and Probe Design and Handling for qRT-PCR 
 Primers and probes for TaqMan quantitative real-time PCR were designed using 
Beacon Designer version 7.0 (Premier Biosoft, Palo Alto, CA).  The sequences for NIS 
and β-actin were accessed from NCBI and entered into the Beacon Designer software for 
primer and TaqMan probe design for each gene of interest.  Beacon Designer performs 
two searches to detect regions of each gene to avoid in primer/probe design: those that 
could form secondary structure and those that share similar sequences with other genes.  
Secondary structures were analyzed at a folding temperature of 55°C.  Any self-folding 
that involved a stretch of fewer than 10 nucleotides was not considered a problem in 
design.  An NCBI BLASTn search was then performed to determine regions of homology 
between the gene of interest and other Mus musculus genes to prevent non-specific 
amplification.   
 Beacon Designer then provides the option to perform a search for TaqMan 
primer/probes using its default settings for primer length (20-24 nucleotides), primer Tm 
(59 +/- 2°C) , amplicon length (75-150 base pairs), probe length (20-24 nucleotides), and 
probe Tm ( [primer Tm + 10] +/- 2°C).  After obtaining results from these searches for 
each NIS and β-actin, the “best” probes based on the rating number derived from the 
program’s algorithm were further analyzed using specifications for real-time PCR 
outlined by Dorak (2006) to choose an optimal primer/probe set.  Beacon Designer 
displayed seven “best” results for NIS and five for β-actin.  First, if possible, primers 
were selected to produce an amplicon which crosses an exon-intron barrier.  This case 
was possible with a probe designated “best” for NIS PCR; however it was not possible 
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for β-actin.  Prioritization of primer selection was then based on physical properties of 
primers that were paired with “best” rated probes.  Optimal Tm is defined by Dorak as 
between 58-60°C, and primer sets with similar Tm values will have comparable 
efficiencies during the PCR.  The Tm of the probe was chosen to be as close to a 10°C 
higher Tm than the corresponding primers.  The ideal GC% for primer/probe selection is 
between 30-80%.  By keeping GC% within this range, the use of high annealing 
temperatures or cosolvents with the primers is not necessary.  In both primer and probe 
design, choices containing runs of four or more guanine nucleotides were discarded.  The 
amplicon size was also controlled in primer design to an optimum between 50-150 base 
pairs.  This smaller size facilitates a more efficient PCR, and therefore more consistent 
results.  The parameters of the selected primer/probe combinations are found in Table 2.     
 Primers and probes for TaqMan quantitative real-time PCR were purchased from 
Applied Biosystems (Foster City, CA).  Primers were received at a concentration of 100 
µM and suspended in 1X TE.  A 100 µl aliquot of the stock primer solutions were further 
diluted in nuclease-free H2O to a concentration of 12.5 µM.  Both NIS and β-actin 
TaqMan probes were labeled on the 5’ end with a 6FAM fluorophore and a 3’ TAMRA 
quencher.  The 100 µM stock of probe was diluted 1/20 to make 5 µM aliquots, all of 
which were stored at -20°C. 
 
Generation of cRNA Standard 
 To create a cRNA standard for quantification of one-step real-time PCR 
transcripts, a PCR product of each gene of interest was cloned, transformed, linearized, 
and in vitro transcribed.  For cloning and bacterial transformation, the TOPO TA cloning 
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kit (Invitrogen, Carlsbad, CA) was used following the manufacturer’s protocol for 
OneShot chemical transformation using DH5α-T1 competent cells into a pCRII-TOPO 
vector.  Cells were plated on LB plates containing 50 µg/ml ampicillin at volumes of 30, 
60, and 100 µl.  Single bacteria colonies were picked and cultured overnight.  DNA was 
purified from bacteria cultures using Wizard Plus SV Miniprep DNA Purification System 
(Promega) following the manufacturer’s protocol.  To determine if purified DNA 
incorporated the desired insert, a 20 µl EcoRI restriction enzyme digest was performed 
on each sample of purified DNA and separated on a 1.2% agarose gel.  For all samples 
that contained the a band of the molecular size of the desired insert, 50% glycerol stocks 
of overnight bacteria culture were made and stored at -20°C.  Plasmid DNA was then 
sequenced using the ABI 3100-Avant Genetic Analyzer (Applied Biosystems).  ABI 
BigDye 3.1 sequencing reactions were prepared according to the manufacturer’s protocol, 
followed by ethanol precipitation containing 125 mM EDTA.  Pelleted DNA was 
resuspended in ABI Hi-Di formamide and sequenced according to the manufacturer’s 
protocol for ABI 3100-Avant sequencing.  BLAST nucleotide searches were performed 
on successful sequences to confirm the insertion of the entire insert within the plasmid 
DNA.  Only plasmid DNA containing insert sequences of 100% identity to the published 
sequence for the gene of interest as well as containing the PCR primers used for insert 
amplification were used for further analysis. 
 In preparation for DNA purification, bacteria from glycerol stocks of samples that 
had been sequenced and confirmed to have incorporated the insert into plasmid DNA 
were grown overnight in 150 ml LB broth containing 50 µg/ml ampicillin.  Plasmid DNA 
was purified from this bacterial culture using a Bio-Rad Midiprep kit according to 
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manufacturer’s protocol with the following modifications.  During the initial 
centrifugation of overnight culture, three spins containing 50ml of culture each were 
performed for 10 minutes at 7000 RPM.  Also, the DNA elution step was performed with 
300 µl of sdd H2O rather than the 600 µl recommended by the manufacturer.  The 
concentration of purified DNA was then measured using a NanoDrop spectrophotometer.   
 Plasmid DNA was linearized for in vitro transcription using the protocol for 
preparation of linearized template DNA from plasmid DNA adapted from Sambrook 
(2001).  The restriction enzyme Bam HI was used for digestion to cut the plasmid DNA 
at a site that does not separate the T7 promoter contained in the pCRII-TOPO plasmid 
from the PCR insert.  Plasmid DNA was purified by extractions using equal volumes of 
phenol/chloroform:isoamyl alcohol followed by 24:1 chloroform:isoamyl alcohol, and 
then precipitated with 3 M sodium acetate and cold ethanol.  The product of the 
linearization was analyzed by agarose gel electrophoresis to ensure that a significant 
amount of circular plasmid DNA did not remain.  Purified linearized DNA was 
resuspended in 1X TE and stored at 4°C.   
 Linearized DNA was in vitro transcribed from an adapted protocol for probe 
synthesis described in Sive et al. (2000) using a T7 RNA polymerase (Promega) and un-
labeled rNTPs.  Following the RNA synthesis reaction, samples were treated with 1 µl of 
RQ1 DNaseI I (Promega) at a concentration of 1 U/µl to remove residual DNA template.  
Probe integrity was assessed by 1.2% agarose gel electrophoresis.  If a single band of the 
predicted molecular size of the RNA transcript was detected on the gel, purification of 
the RNA standard using the column based RNeasy Min-Elute Cleanup kit (Qiagen) was 
used to remove unincorporated nucleotides following the manufacturer’s protocol.  
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Following RNA elution, RNA standard integrity and yield was again assessed by agarose 
gel electrophoresis.  The RNA eluent was diluted 1:10 in nuclease-free H2O and stored at 
-80°C.   
 Quantification and dilution of cRNA standards was performed following the 
protocol outlined by Fey et al. (2004).  Briefly, cRNA concentrations were quantified 
spectrophotometically using a NanoDrop spectrometer after heating for 5 minutes at 
60°C.  A dilution series was created in a range of 0.001 fg to 1 ng in nuclease-free H2O.  
 
One-Step Real-Time PCR 
 Real-time PCR analysis was performed on DNaseI I treated experimental samples 
and cRNA standards in 50 µl singleplex reactions using the iScript One-Step RT-PCR kit 
for probes (Bio-Rad) in a Bio-Rad iCycler according to the manufacturer’s instructions 
under the following conditions.  Each forward and reverse primer for NIS and β-actin 
(See Table 2) was added at a 500 nM final concentration.  TaqMan probes designed with 
a 6FAM fluorophore and TAMRA quencher (See Table 2) were added at 200 nM final 
concentration, and 500 ng of DNaseI-treated total RNA was used for each experimental 
sample reaction.  The reaction protocol was performed according to the manufacturer’s 
instructions beginning with cDNA synthesis for 10 minutes at 50°C followed by a reverse 
transcriptase inactivation for 5 minutes at 95°C.  PCR cycling and detection consisted of 
40 cycles of 15 seconds at 95°C and a data collection step of 30 seconds at 55.5 °C.   
Experimental samples were comprised of tissues collected from imaged mice to 
quantitated NIS mRNA.  Palpable tumors and portions of these tumors which 
demonstrated radioiodide uptake were compared with tumors containing regions of no 
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radioiodide uptake activity.  MMTV-infected mammary glands which had not developed 
palpable tumors were also examined.  To compare these MMTV-infected mice with 
uninfected normal mice, mammary glands from nulliparous, multiparous, and lactating 
C57BL/6J mice were used.  Thyroid was used as a positive control for NIS mRNA 
expression, and liver was used as a negative control.  Each reaction was performed in 
duplicate.  A parallel NIS and β-actin cRNA dilution series in a range of 0.001 fg to 1 ng 
was run to produce a standard curve for quantification of experimental mRNA 
transcripts.   
 
Data Analysis 
 Real-time PCR results were analyzed using the critical threshold (Ct) value 
converted to mRNA transcript copy number using a cRNA standard curve.  Ct values 
were determined by the Bio-Rad software, which designates the point at which the 
detection system reads a fluorescent signal associated with an exponential amplification 
of PCR product.  Quantification of mRNA transcripts was determined using a 
combination of the methods described by Fronhoffs et al. (2002) and Fey et al. (2004).  
Briefly, a standard curve was created by plotting Ct values against the log of ng of cRNA 
standards for each gene.  Unknown samples of NIS and β-actin were quantified using 
experimentally determined Ct values inserted to the equation of the line for each gene’s 
standard curve.  The conversion to mass units derived from the standard curve was 
performed by using the equation of the line of the linear regression analysis from each 
standard curve (Figures 1A and 1B).  Using the calculated mass units of sample 
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transcript, we then calculated mRNA starting copy number using the following formula 
adapted from Lee, et al. (2008). 
      RNA copy number = (ng/mol) tideribonucleoMW  x y)(bases/coplength  transcript
 l)(copies/mo 10^23 x 6.022 x (ng)t  transcripsample of mass
 
The approximate molecular weight of a ribonucleotide within a region of single stranded 
RNA, 3.205x1011 (ng mol-1 bases-1), was used for calculations (Applied Biosystems).  The 
exact MW of each transcript was calculated, but was not found to be significantly 
different than the approximation used above.  The transcript lengths for NIS and β-actin, 
including regions of plasmid DNA between the T7 promoter and BAM HI restriction 
enzyme cut site in addition to PCR inserts, were 243 and 218 nucleotides, respectively.     
Finally, a ratio of NIS copy number to β-actin mRNA copy number was calculated, using 
β-actin as an internal control for mRNA levels.  The efficiency of each real-time 
experiment was determined using the slope of the standard curve with the following 
equation:  
Efficiency = 10-1/slope – 1, 
with the slope determined from the equation of the linear regression curve of the dilutions 
of cRNA standard (Figures 1A and 1B).   
To examine the relationship between radioiodide uptake and mRNA abundance, 
the ratio of NIS: β-actin was compared to the intensity and pattern of pixels within each 
ROI demonstrating radioiodide uptake.  The abundance of NIS mRNA was correlated 
with one of two patterns of iodide uptake defined by our group in ROI analysis.  The 
center-to-edge pattern describes radioiodide accumulation originating from a single 
location and spreading from this single starting point.  Tumors exhibiting a multi-spot 
pattern demonstrated more than one region of initial radioiodide uptake.    
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TABLE 1: Primers used for Non-quantitative RT-PCR 
Gene NCBI Accession # Sequence Tm 
(°C) 
GC% Amplicon 
Size (bp) 
Ref. 
F 5’-CTGTACCCGCCTGGAGAG– 3’ 57.3 66.6 NIS NM_053248 
R 5’-CCAGAGCCCCGTAGTAGAGA– 3’ 57.6 60.0 
201 Primer3 
F 5’-AACTTTGGCATTGTGGAAGG– 3’ 53.8 45.0 GAPDH NM_008084 
R 5’-GGATGCAGGGATGATGTTCT– 3’ 54.7 50.0 
132 Primer3 
F 5’-AACACCCCAGCCATGTACGTAG– 3’ 59.1 54.5 
R 5’-GTGTTGGCATAGAGGTCTTTACGG– 3’ 57.5 50.0 
β-Actin NM_007393 
R 5’-ATAGATCATGGGCGGTTCAG– 3’ 54.4 50.0 
550 Perron,, 
2001 
 
 
 
TABLE 2: Primers and Probes used for TaqMan qRT-PCR 
Gene NCBI 
Accession # 
Sequence Tm 
(°C) 
GC% Beacon 
Rating 
Amplicon Size 
(bp) 
F- 5’- GCTCTCATTCATCTATGGCTCAAC-3’ 58.5 45.8 78.3 
R- 5’-GGTGAAAGCGCCAAGGAGAG -3’ 59.3 60.0 59.6 
NIS NM_053248 
Probe- 5’-6FAM- 
TGTGGCTGCTCTGTCCTCGCTGCT-TAMRA -3’ 
69.2 62.5 87.8 
130 
F- 5’-TGTTTTGTTTTGGCGCTTTTGAC -3’ 58.9 39.1 82.4 
R- 5’ -TCAGCCACATTTGTAGAACTTTGG -3’ 58.7 41.7 57.9 
β-actin NM_007393 
Probe- 5’-6FAM-
TGCTCCAACCAACTGCTGTCGCCT-TAMRA -3’ 
67.9 58.3 73.3 
105 
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RESULTS 
cRNA Standard Curves 
To determine the copy number of both NIS and β-actin transcripts in real-time 
RT-PCR analysis, we established standard curves using cRNA generated by in vitro 
transcription which was serially diluted in nuclease-free H2O.  cRNA standards were 
serially diluted in a range from 1 ng to 0.001 fg for each gene.  Standard curves were 
generated for NIS and β-actin by plotting the Ct value versus log ng of cRNA standard 
(Figures 1A and 1B).  A strong linear relationship was observed with a correlation 
coefficient of r2>0.99.  The efficiency of real-time amplification was also determined for 
of each cRNA curve.  This efficiency calculation expresses the percentage to which each 
DNA template replicates itself per PCR cycle.  Using the slope determined by the linear 
regression of the standard curve, the efficiency of amplification was 112% and 110% for 
NIS and β-actin, respectively.  These values are at the upper range of acceptable limits 
for efficiency (Applied Biosystems).    
 
MMTV- NIS mRNA Expression Controls: Thyroid and Liver 
Confirmation of Primer Specificity and Sequence Analysis 
 In order to ensure that TaqMan primers for NIS and β-actin were specific for our 
genes of interest we performed non-quantitative RT-PCR to measure amplicon length, 
ensure the amplification of a single product, and verify the nucleotide sequence of each 
amplicon.  Non-quantitative RT-PCR was performed using RNA from the thyroid of an 
MMTV mouse (mouse 240).  Following RT-PCR, products were separated on 1.2% 
agarose gels.  Products appeared at the expected molecular sizes; 130 base pairs and 105 
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base pairs for NIS and β-actin, respectively, without the presence of extraneous bands 
(Figure 2).  Following cloning into a pCRII-TOPO vector, sequence analysis of the NIS 
and β-actin clones showed 100% identity with published sequences of each gene. 
      
mRNA Quantification for Positive and Negative NIS Controls 
 The review by Dohan et al. (2003a) documents NIS mRNA expression in thyroid 
tissue, and no expression of NIS in liver tissue samples.  Using these findings, we used 
thyroid as a positive tissue control and liver as a negative tissue control for NIS mRNA 
expression.  We measured NIS and β-actin mRNA expression in thyroid and liver in an 
MMTV mouse (mouse 240).  High levels of radioiodide uptake compared to background 
were recorded in the thyroid using gamma camera imaging (Figure 3A).  Conversion of 
mean Ct values of three real-time RT-PCR replicates to mRNA transcript numbers 
revealed that the MMTV (mouse 240) thyroid contained 1.01x104 NIS transcripts, 
compared with 3.62 x106 β-actin transcripts per 500 ng of total RNA.  Liver mRNA was 
subjected to real-time RT-PCR and amplification did not cross the critical threshold 
following 40 PCR cycles, indicating little to no NIS expression (Figure 3A).  β-actin 
transcript number in liver mRNA was calculated to be 1.38 x107 per 500 ng of total RNA.  
The NIS:β-actin ratio of thyroid and liver reveals that, when controlled for mRNA 
expression with an internal control gene, thyroid serves as a positive control for NIS 
mRNA expression while liver is a suitable negative control (Figure 3B).    
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MMTV-induced Mammary Tumors 
 In order to determine the level of NIS mRNA in mouse mammary tumors, we 
performed real-time RT-PCR on whole tumors or pieces of tumors (Table 3).  We then 
compared the ratio of NIS mRNA to β-actin mRNA with the radioiodide uptake as 
revealed by gamma camera imaging.  Below we present data from each of the analyzed 
tumors (Table 4).  All data are presented as the NIS:β-actin ratio alongside a gamma 
camera image of the mouse. 
 
Mouse 168: KI Blocked Mammary Tumor 
 The right thoracic mammary tumor of the MMTV-infected mammary tumor, 
which had been blocked with potassium iodide, was examined using real-time RT-PCR.  
KI blocking has the effect of reducing thyroid gland radioiodide uptake and preventing 
possible thyroid cell damage.  It is not shown to affect tumor uptake in previous studies.  
The gamma camera image of this tumor indicates an increased radioiodide uptake above 
background throughout the area of the tumor, with a region of higher intensity in the 
center of the tumor (Figure 4).  NIS and β-actin mRNA transcript numbers in this sample 
were calculated from the mean Ct value of one duplicate real-time reaction for each gene.  
The level of NIS transcripts was calculated to be 2.59x103, while the level of β-actin was 
calculated at 1.19x108 copies, each per 500 ng of total RNA. 
 
Mouse 209: Mammary Tumor Cut into Four Pieces 
 The left thoracic mammary tumor of (mouse 209) was cut into four pieces and 
used for real-time RT-PCR.  The exact position of each piece in relation to the gamma 
camera image was not documented in these tumors, reflecting a change in protocol 
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between the time of tumor imaging and real-time processing in this instance.  The gamma 
camera image of this tumor shows an increase in radioiodide uptake above background, 
with the anterior region of the tumor producing the highest level of uptake (Figure 5A).  
The ROI data confirms that the region at the anterior portion of the tumor shows an 
increase in radioiodide uptake compared with the other regions of the tumor (Figure 5B).  
ROI analysis identified this tumor as a center-to-edge pattern, which we have found to 
correlate with younger, still developing tumors.  The mRNA transcript levels of NIS and 
β-actin cannot be correlated with the gamma camera image in this case, but differences in 
mRNA levels were documented between pieces of the tumor.  Tumor morphology was 
documented prior to RNA extraction, and found each piece to be dense, white, tumor 
tissue.  Piece 1 expressed 2.59x103 copies of NIS and 8.22x107 copies of β-actin per 500 
ng of total RNA.  Piece 2 expressed 4.22x103 copies of NIS and 2.15x106 copies of β-
actin per 500 ng of total RNA. The third tumor piece was found to express 2.28x104 NIS 
transcripts and 8.85x107 β-actin transcripts per 500 ng of total RNA.  Piece 4 expressed 
9.99x103 copies of NIS and 5.26x107 copies of β-actin per 500 ng of total RNA.  The 
comparison of NIS:β-actin ratio between the tumor pieces indicates that tumor piece two 
expressed significantly more mRNA than the other three tumor pieces when corrected for 
total mRNA expression (Figure 5C). 
 
Mouse 229: Three Mammary Tumors Each Cut into Two Pieces 
 MMTV-infected (mouse 229) developed tumors in the right thoracic, right 
inguinal, and left abdominal mammary glands.  Each tumor was excised and cut into two 
pieces, however, because these tumors were excised and frozen prior to the design of this 
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experiment, the exact position of the cut in relation to the gamma camera image was not 
documented.   
 The right thoracic tumor was the largest and showed the highest quantity of 
radioiodide uptake among the three tumors (Figure 6A).  The pattern of radioiodide 
uptake has not been examined using ROI analysis, but appears to be in the center-to-edge 
category.  Both pieces of this tumor showed a dense, white morphology.  Upon mRNA 
quantification with real-time PCR, this pieces A and B of this tumor expressed 3.24x103 
and 2.49x103 NIS transcripts while expressing 8.85x107 and 7.08x107 β-actin transcripts 
per 500 ng of total RNA, respectively.  When comparing NIS:β-actin ratio, both pieces A 
and B of the right thoracic tumor expressed more NIS mRNA than pieces of the two other 
tumors (Figure 6B). 
 The right inguinal tumor showed significant radioiodide uptake though not as 
high as the right thoracic tumor (Figure 6A).  The pattern of radioiodide uptake was not 
examined with ROI analysis, but again appeared to have a center-to-edge character.  The 
morphology of the tumor was dense and white.  When examined with real-time PCR, 
piece A of the tumor expressed 1.71x103 NIS transcripts and 7.08x107 β-actin transcripts 
per 500 ng of total RNA.  Tumor piece B expressed 7.50x102 NIS transcripts and 
7.08x107 β-actin transcripts per 500 ng of total RNA.     
 The left abdominal tumor demonstrated a large decrease in radioiodide uptake 
from the other two tumors on this animal (Figure 6A).  However, radioiodide 
accumulation did occur.    The morphology of this tumor included regions of necrosis, 
but still consisted largely of dense, white tissue.  mRNA quantification with real-time 
PCR showed that piece A expressed fewer NIS transcripts than piece B, 9.89x101 
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compared to 3.82x102 per 500 ng of total RNA.  β-actin mRNA expression in piece A 
compared to piece B was also measured, with A expressing 8.85x107 transcripts and B 
expressing 1.19x108 per 500 ng of total RNA.  The left abdominal tumor demonstrated 
the lowest NIS:β-actin ratio among the three tumors in (mouse 229) (Figure 6B).  
 
Mouse 240: Mammary Tumor Cut into Five Pieces 
 The left inguinal tumor of (mouse 240) was separated into five pieces and 
corresponding designations were indicated on the gamma camera image and ROI analysis 
plot (Figures 7A and 7B).  Through ROI analysis, this tumor was identified as having a 
multi-spot uptake pattern.  We have found this pattern to correlate with older tumors.  
Within the tumor, Piece 1 had the most radioiodide uptake, while Piece 5 displayed the 
lowest amount of radioiodide uptake on gamma camera images.  The morphology of 
pieces 2-5 appeared white and dense.  However, tumor piece 1 had large regions of 
necrosis and largely bloody prior to mRNA extraction.  Each individual piece of the 
tumor was then used in real-time RT-PCR where NIS and β-actin copy numbers were 
determined.  NIS and β-actin transcript numbers were 8.09x102 and 1.38x108 per 500 ng 
of total RNA, respectively in Piece 1.  In Piece 2, NIS mRNA expressed 2.02x102 copies, 
while expressing 5.26x107 copies of β-actin mRNA per 500 ng of total RNA.  Piece 3 
expressed 1.32x103 copies of NIS mRNA and 9.54x107 copies of β-actin mRNA per 500 
ng of total RNA.  In piece 4, it was calculated that the tumor expressed 6.89 copies of 
NIS and 7.08x107 copies of β-actin mRNA per 500 ng of total RNA.  These values 
resulted after four replicates of both NIS and β-actin real-time runs, with two of the four 
providing quantities of NIS mRNA that did not cross the critical threshold before cycle 
 38 
40.  Piece 5 of this tumor expressed 2.40x103 copies of NIS mRNA and 7.63x107 copies 
of β-actin mRNA per 500 ng of total RNA, the highest amount within this tumor.  Tumor 
piece 5 showed over a two-fold increase in NIS mRNA expression compared to any of 
the other pieces within this tumor when normalized to β-actin expression, while piece 3 
exhibited a two-fold increase over both pieces 1 and 2 (Figure 7C). 
  
Mouse 258: Mammary Tumor Piece 
 The right thoracic mammary tumor of (mouse 258) was used in real-time RT-
PCR.  The piece of the tumor used in these experiments was the half toward the center of 
the animal. This region appeared white and dense, while the outer region appeared more 
bloody and necrotic.  The gamma camera image shows increased radioiodide uptake 
above background throughout the tumor (Figure 8B).  It also shows a higher intensity of 
radioiodide signal in the inner region of the tumor which was used in these real-time 
experiments.  The NIS and β-actin copy numbers were calculated from the mean Ct of 
three replicate real-time reactions for each gene.  Transcript numbers of NIS and β-actin 
mRNA were calculated as 9.61x102 and 7.08x107 per 500 ng of total RNA, respectively.  
 
MMTV- Non-Palpable Tumor Mammary Glands 
 We investigated NIS expression in mammary glands of MMTV mice lacking 
palpable tumors as a reference for any changes in expression demonstrated by tumor 
tissues.  In addition, we aimed to measure increases in NIS expression at the earliest stage 
of tumor development.  In order to determine the level of mRNA expressed in mammary 
glands with non-palpable tumors of MMTV-infected mice, we performed real-time RT-
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PCR and compared NIS:β-actin transcript ratios with the amount of radioiodide uptake in 
gamma camera images.   
 
Mouse 256 Non- Tumor Mammary Gland 
 The left inguinal mammary gland of (mouse 256) was excised and NIS mRNA 
transcript levels were examined using real-time RT-PCR.  The gamma camera image of 
this mammary gland displays radioiodide uptake slightly above the background level 
(Figure 8A).  When mean Ct values of duplicate RT-PCR runs were converted into 
mRNA transcript number, NIS was expressed at 2.49x103 mRNA transcripts, while β-
actin was expressed at a level of 4.06x107 transcripts per 500 ng of total RNA.  When 
NIS:β-actin transcript ratios were compared with other non-tumor mammary glands in 
MMTV-mice, (mouse 256) showed a normalized NIS expression ratio in between that of 
the small tumor in (mouse 258) and the non-tumor mammary gland showing no 
radioiodide uptake in (mouse 262) (Figure 8D). 
 
Mouse 258 Non-Palpable Small Tumor 
 The left inguinal mammary gland of (mouse 258) was examined by comparing 
NIS mRNA transcript ratio with the internal control β-actin with the amount of 
radioiodide uptake above background in the gamma camera image.  The level of 
radioiodide uptake in the left inguinal mammary gland of the mouse is significantly 
higher than background (Figure 8B).  Real-time RT-PCR analysis of four replicate 
samples showed that NIS transcripts were expressed at a level of 1.01x103 and β-actin 
transcripts were expressed at a level of 8.05x106 per 500 ng of total RNA.  The NIS:β-
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actin transcript ratio in the small tumor in (mouse 258) showed much greater normalized 
NIS mRNA expression than the large, developed tumor in the right thoracic region of 
same animal (Figure 8E). 
  
Mouse 262 Non-Tumor Mammary Gland 
 The left inguinal mammary gland of (mouse 262) was observed for the amount of 
radioiodide accumulation above background compared with the amount of NIS mRNA.  
The gamma camera image does not appear to have radioiodide uptake above the level of 
background in the region of the left inguinal mammary gland (Figure 8C).  In a duplicate 
real-time reaction, the levels of NIS mRNA and β-actin were calculated to be 1.27x103 
mRNA transcripts and 3.49x107 mRNA transcripts per 500 ng of total RNA, respectively.   
 
C57- Lactating, Multiparous and Nulliparous Mammary Glands 
NIS mRNA Expression in C57 Mammary Glands Shown by Non-quantitative RT-PCR 
 Non-quantitative RT-PCR was performed on mammary glands of lactating, 
previously pregnant, and nulliparous C57 mice to determine if NIS mRNA was present in 
each tissue as documented by current literature (Dohan, 2003a).  RT-PCR was performed 
with primers for NIS and β-actin using lactating mice 251 and 253, previously pregnant 
mice 250 and 254, and nulliparous mice 249 and 255.  PCR products were separated on 
1.2% agarose gels, and stained with ethidium bromide to visualize bands.  Bands of the 
expected molecular size (201 base pairs) were observed in all of the above tissues (Figure 
9).  No RT negative controls were performed for each primer set in each reaction. 
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mRNA Quantification in Lactating Mammary Glands in C57 Mice 
 To determine the differences in NIS mRNA expression between the three 
categories of C57 mammary glands, real-time RT-PCR was performed on samples from 
each set.  Lactating mammary glands from (mice 251 and 253) were examined using real-
time RT-PCR.  The right axillary gland from (mouse 251) and the left axillary gland from 
(mouse 253) were used in experiments.  Both glands showed high levels of radioiodide 
uptake by gamma camera imaging (Figures 10A and 10B).  When analyzed with real-
time RT-PCR, (mouse 251) was found to have 5.48x103 NIS transcripts and 1.80x107 β-
actin transcripts per 500 ng of total RNA when derived from mean Ct values of six 
replicates.  In (mouse 253), duplicates real-time reactions produced 1.63 x104 NIS 
transcripts and 8.51x106 β-actin transcripts per 500 ng of total RNA.  The lactating 
mammary glands each show increased NIS mRNA expression compared to previously 
pregnant and nulliparous animals (Figure 10E).  However, (mouse 251) expresses much 
less NIS mRNA than (mouse 253). 
  
mRNA Quantification in Mammary Glands of Previously Pregnant C57 Mice 
 To measure the quantity of NIS mRNA transcripts in previously pregnant, 
multiparous C57 mice, real-time PCR was performed on the right inguinal mammary 
gland of (mouse 250).  In the gamma camera image of this animal, radioiodide uptake 
was not above background levels (Figure 10C).  When transcript copy number was 
derived following real-time PCR, 3.77x103 NIS mRNA transcripts and 2.90x107 β-actin 
transcripts per 500 ng of total RNA were recorded.   
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mRNA Quantification in Mammary Glands of Nulliparous C57 Mice 
 To determine the level of NIS mRNA expression in mammary glands of 
nulliparous (virgin) C57 mice, we performed real-time RT-PCR on the right axillary 
mammary gland of (mouse 255).  The gamma camera image of this mouse does not 
demonstrate a level of radioiodide uptake above background in the region of the right 
axillary mammary gland (Figure 10D).  When transcript numbers of NIS and β-actin 
were calculated, NIS mRNA transcripts were detected at a level of 3.12x103, while β-
actin transcripts were present at levels of 1.10x107 per 500 ng of total RNA. 
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Table 3. Raw data from real-time RT-PCR.  Input total RNA for each sample was 500 ng.   
Letters designate when a new DNaseI treatment is performed on original RNA extraction.  
Numbers following a letter or a hyphen designate the number of freeze-thaw cycles each 
DNased RNA has undergone.  No letter or number indicates freshly DNased RNA that 
has not been frozen. 
 
Mouse# -
Tissue 
NIS 
Ct 
1 
NIS 
Ct 2 
NIS 
Ct 3 
NIS 
Ct 4 
NIS 
Ct 5 
NIS 
Ct 6 
NIS 
Mean 
Ct 
NIS 
SD 
NIS 
%CV 
Actin 
Ct 1  
Actin 
Ct 2 
Actin 
Ct 3 
Actin 
Ct 4 
Actin 
Ct 5 
Actin 
Mean 
Ct 
Actin 
SD 
Actin 
%CV 
168 KI 
Blocked 
MMTV 
Tumor 
 
27.1 29.8 
 
    28.45 1.35 4.75 13.2 
 
12.7    12.95 0.25 1.93 
209-1 
MMTV 
Tumor 
Piece 
 
28.1 28.8     28.45 0.35 1.23 13.7 14    13.85 0.15 1.08 
209-2 
MMTV 
Tumor 
Piece 
 
28.7 28.7 27.1a 27.5a 27.0a1  27.8 0.75 2.70 18.6 18.6 13.4a 13.1a 14.1a1 15.56 2.5 16.07 
209-3 
MMTV 
Tumor 
Piece 
 
25.6 25.5     25.55 0.05 0.196 13.6 13.6    13.6 0 0 
209-4 
MMTV 
Tumor 
Piece 
 
26.7 26.6     26.65 0.05 0.188 14.3 14    14.15 0.15 1.06 
229-RT-A 
Tumor 
Piece 
 
27.9      27.9 N/A N/A 13.6     13.6 N/A N/A 
229-RT-B 
Tumor 
Piece 
 
28.5      28.5 N/A N/A 13.9     13.9 N/A N/A 
229-RI-A 
Tumor 
Piece 
 
29      29 N/A N/A 13.9     13.9 N/A N/A 
229-RI-B 
Tumor 
Piece 
 
30.1      30.1 N/A N/A 13.9     13.9 N/A N/A 
229-LA-
ATumor 
Piece 
 
32.8      32.8 N/A N/A 13.6     13.6 N/A N/A 
229-LA-B 
Tumor 
Piece 
 
31      31 N/A N/A 13.2     13.2 N/A N/A 
240-1 
MMTV 
Tumor 
Piece 
 
N/A 30     30 N/A N/A 13 13.1    13.05 0.05 0.383 
240-2 
MMTV 
Tumor 
Piece 
 
34.4 29.3     31.85 2.55 8.01 14.3 14.1    14.2 0.1 0.704 
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240-3 
MMTV 
Tumor 
Piece 
 
29.9 28.8     29.35 0.55 1.87 13.5 13.3    13.4 0.1 0.746 
240-4 
MMTV 
Tumor 
Piece 
 
N/A N/A 37.6a 35.1a1   36.35 1.25 3.44 13.9 13.9 12.8a 14a1  13.65 0.49 3.59 
240-5 
MMTV 
Tumor 
Piece 
 
28.3 28.8     28.55 0.25 0.876 13.8 13.8    13.8 0 0 
258 MMTV 
Tumor 
Piece 
 
29.6 29.3 30.4a    29.77 0.46 1.55 13.9 14.2 14.0-
1 
  14.03 0.125 0.891 
258 MMTV 
Small 
Tumor 
 
33.7 28.6 28.4a 28.1a   29.7 2.3 7.74 19 19.1 14.6a 14.6a  16.825 2.225 13.22 
256 MMTV 
Non Tumor 
Mammary 
Gland 
 
28.2 28.8     28.5 0.3 1.05 14.7 14.6    14.65 0.05 0.341 
262 MMTV 
Non Tumor 
Mammary 
Gland 
 
30 28.8     29.4 0.6 2.04 14.7 15    14.85 0.15 1.01 
251 C57 
Lactating 
Mammary 
Gland 
 
31.5 30.9 25.8a 26.2a1 25.2a2 25.1a2 27.45 2.68 9.76 16.4 
 
16.4 15a 15.7a1 15.2a2 15.74 0.585 3.72 
253 C57 
Lactating 
Mammary 
Gland 
 
25.9 26.1     26 0.1 0.385 17 16.5    16.75 0.25 1.49 
250 C57 
Multiparous 
Mammary 
Gland 
 
27.9 28     27.95 0.05 0.179 15.1     15.1 N/A N/A 
255 C57 
Nulliparous 
Mammary 
Gland 
 
28.2      28.2 N/A N/A 16.4     16.4 N/A N/A 
240-
MMTV 
Thyroid 
 
26.7 26.3-
1 
26.9-
1 
   26.63 0.25 0.939 17.9     17.9 N/A N/A 
240-
MMTV 
Liver 
 
N/A      N/A N/A N/A 16.1     16.1 N/A N/A 
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Table 4. NIS copy number, β-actin copy number, and NIS:β-actin ratio. 
 
Mouse # and Tissue NIS transcripts β-actin transcripts NIS:β-actin Ratio 
168 KI Blocked MMTV 
Tumor 
 
4.90x103 2.26x108             2.17 x10-5 
209-1 MMTV Tumor Piece 
 
4.90x103 1.56x108 3.15 x10-5 
 
209-2 MMTV Tumor Piece 
 
7.99x103 4.07x106 1.96 x10-3 
 
209-3 MMTV Tumor Piece 
 
4.32x104 1.68x108 2.58 x10-4 
 
209-4 MMTV Tumor Piece 
 
1.89x104 9.97x107 1.90 x10-4 
 
229-RT-A Tumor Piece 
 
6.14x103 1.68x108 3.66 x10-5 
 
229-RT-B Tumor Piece 
 
4.72x103 1.34x108 3.52 x10-5 
 
229-RI-A Tumor Piece 
 
3.25x103 1.34x108 2.42 x10-5 
 
229-RI-B Tumor Piece 
 
1.42x103 1.34x108 1.06 x10-5 
 
229-LA-ATumor Piece 
 
1.87x102 1.68x108 1.12 x10-6 
 
229-LA-B Tumor Piece 
 
7.24x102 2.26x108 3.20 x10-6 
 
240-1 MMTV Tumor Piece 
 
1.53x103 2.62x108 5.85 x10-6 
 
240-2 MMTV Tumor Piece 
 
3.82x102 9.97x107 3.83 x10-6 
 
240-3 MMTV Tumor Piece 
 
2.50x103 1.81x108 1.38 x10-5 
 
240-4 MMTV Tumor Piece 
 
1.13x101 1.34x108 9.72 x10-8 
 
240-5 MMTV Tumor Piece 
 
4.55x103 1.45x108 3.15 x10-5 
 
258 MMTV Tumor Piece 
 
1.82x103 1.34x108 1.36 x10-5 
 
258 MMTV Small Tumor 
 
1.92x103 1.52x107 1.26 x10-4 
 
256 MMTV Non Tumor 
Mammary Gland 
 
4.72x103 7.69x107 6.15 x10-5 
 
262 MMTV Non Tumor 
Mammary Gland 
 
2.40x103 6.62x107 3.63 x10-5 
251 C57 Lactating Mammary 
Gland 
 
1.04x104 3.42x107 3.04 x10-4 
 
253 C57 Lactating Mammary 
Gland 
 
3.08x104 1.61x107 1.91 x10-3 
 
250 C57 Multiparous 
Mammary Gland 
 
7.14x103 5.50x107 1.30 x10-4 
 
255 C57 Nulliparous 
Mammary Gland 
 
5.92x103 2.09x107 2.83 x10-4 
240-MMTV Thyroid 
 
1.92x104 6.86 x106 2.80 x10-3 
240-MMTV Liver 
 
0 2.61x107 0 
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Figure 1. cRNA standard curves.   
 
Standard curves were generated for (A) NIS and (B) β-actin.  Ten-fold serial dilutions of 
cRNA standards were performed in nuclease free H2O, and five dilutions over the range 
of 1 ng to 0.1 fg were quantified using real-time RT-PCR (0.1 fg, 1 fg, 1 pg, 10 pg, 1 ng).  
A standard curve graph is made by plotting Ct value on the y-axis and the log of input 
amount (nanograms of cRNA) on the x-axis.  The slope of the NIS cRNA standard curve 
(A) is -3.0681, the equation of the line is  
y = (-3.0681x + 9.4349), and the correlation coefficient is 0.9972.  The slope of the β-
actin cRNA standard curve (B) is -3.0964, the equation of the line is  
y = (-3.0964x + 8.303), and the correlation coefficient is 0.9989.        
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Figure 2. Non-quantitative RT-PCR amplifying NIS and β-actin with TaqMan Primers.   
 
RT-PCR was performed on thyroid RNA extracted from an MMTV-mouse (mouse 240) 
using TaqMan primers designed for real-time RT-PCR.  NIS PCR product appeared as a 
single band at 130 base pairs (Lane 2) and β-actin PCR product appeared as a single band 
at 105 base pairs (Lane 4) as measured by a 1Kb+ ladder (Lane 1).  No RT controls were 
performed for each gene (Lanes 3 and 5). 
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Figure 3. Positive and negative control tissues for NIS mRNA expression.   
 
Thyroid gland and liver, designated by red box, of an MMTV mouse (mouse 240) were 
imaged with the gamma camera (A).  Thyroid revealed high levels of radioiodide uptake, 
while liver did not accumulate radioiodide above background levels.  Real-time PCR was 
performed using 500 ng of total RNA extracted from each tissue to record levels of NIS 
and β-actin mRNA.  The mean Ct values for each gene were converted into transcript 
copy number.  Data are presented as a ratio of NIS: β-actin transcript copy number (B).  
Thyroid expressed NIS mRNA, proving it to be a suitable positive control, while liver did 
not produce a signal for NIS following 40 real-time PCR cycles, exhibiting its suitability 
as a negative control. 
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Figure 4. MMTV-mouse (mouse 168) with potassium iodide blocking.   
 
The gamma camera image of KI-blocked MMTV mouse (mouse 168) showed 
accumulation of radioiodide in right thoracic (RT) tumor, designated by a red box.  KI 
blocking has the effect of reducing thyroid gland radioiodide uptake and preventing 
possible thyroid cell damage.  It is not shown to affect tumor uptake in previous studies.  
Real-time RT-PCR was performed on this tumor to determine NIS and β-actin mRNA 
levels. 
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Figure 5. Comparison of radioiodide uptake and NIS mRNA level in MMTV mouse 
(mouse 209) which has developed one mammary tumor.   
 
MMTV-infected mouse (mouse 209) was imaged with the gamma camera and revealed 
radioiodide uptake in the left thoracic (LT) mammary tumor (A).  The region of this 
tumor, marked by a red box, was investigated with ROI analysis (B), displaying a center-
to-edge pattern of radioiodide uptake.  The tumor was removed and separated into four 
sections (209-1, 209-2, 209-3, and 209-4).  The orientation of these pieces in relation to 
the gamma camera image was not recorded.  Real-time PCR was performed using 500 ng 
of total RNA extracted from each tumor piece to record levels of NIS and β-actin mRNA.  
The mean Ct values for each gene were converted into transcript copy number.  Data are 
presented as a ratio of NIS: β-actin transcript copy number (C).    
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Figure 6. Comparison of radioiodide uptake and NIS mRNA level in MMTV mouse 
(mouse 229) which has developed three mammary tumors.   
 
MMTV-infected mouse (mouse 229) was imaged with the gamma camera and revealed 
radioiodide uptake in right thoracic (RT), right inguinal (RI), and left abdominal (LA) 
mammary tumor tumors(A).  The RT tumor exhibited the most radioiodide uptake, while 
the RA tumor showed the least radioiodide uptake.  Each tumor is marked with a red box 
encompassing the region of the tumor which was excised and examined with real-time 
RT-PCR.  Following removal, each tissue was split into two pieces (A and B).  The 
orientation of the tumor halves in relation to the gamma camera image was not recorded.  
Real-time PCR was performed using 500 ng of total RNA extracted from each tumor 
piece to record levels of NIS and β-actin mRNA.  The mean Ct values for each gene were 
converted into transcript copy number.  Data are presented as a ratio of NIS: β-actin 
transcript copy number (B).  Increased mRNA level correlates with increased radioiodide 
uptake in the comparison of the three tumors, as the RT tumor contains the highest 
NIS:β-actin ratio in addition to the highest level of radioiodide accumulation within the 
tumor.  The RI tumor has the second highest levels of NIS: β-actin ratio and radioiodide 
uptake.  The LA tumor has the lowest levels of each.     
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Figure 7. Comparison of radioiodide uptake and NIS mRNA level in MMTV mouse 
(mouse 240) which has developed one mammary tumor.   
 
MMTV-infected mouse (mouse 240) was imaged with the gamma camera and revealed 
radioiodide uptake in a left inguinal (LI) mammary tumor (A).  The region of this tumor, 
marked by a red box, was investigated with ROI analysis (B), displaying a multi-spot 
pattern of radioiodide uptake.  The tumor was removed and separated into five sections 
(240-1, 240-2, 240-3, 240-4, and 240-5).  The orientation of these pieces in relation to the 
gamma camera is presented in the ROI image (B).  Real-time PCR was performed using 
500 ng of total RNA extracted from each tumor piece to record levels of NIS and β-actin 
mRNA.  The mean Ct values for each gene were converted into transcript copy number.  
Data are presented as a ratio of NIS: β-actin transcript copy number (C).  The mRNA 
levels in the tumor pieces do not correlate with increased radioiodide uptake in the pieces 
of this tumor.  Tumor piece 240-5 has the lowest amount of radioiodide uptake as seen in 
the ROI analysis (B), but contains the highest ratio of NIS:β-actin transcripts.  
Additionally, pieces 240-1 and 240-2 reveal the highest radioiodide uptake in ROI 
analysis; however they possess the lower ratios of NIS: β-actin transcripts than piece 240-
5.   
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Figure 8. Comparison of radioiodide uptake and NIS mRNA level in multiple MMTV 
mice (mouse 256, mouse 258, and mouse 262) in mammary glands with non-palpable 
tumors.   
 
An MMTV-infected mouse (mouse 256) was imaged with the gamma camera and 
revealed radioiodide uptake in the right thoracic (RT) mammary tumor.  Radioiodide 
uptake was increased above background levels in the left inguinal non-tumor mammary 
gland, designated by a red box (A).  An MMTV-infected mouse (mouse 258) was imaged 
with the gamma camera and accumulated iodide in a right thoracic tumor as well as a 
mammary gland in the left inguinal region, each designated by a red box (B).  An 
MMTV-infected mouse (mouse 262) developed a left thoracic tumor which accumulated 
radioiodide.  We investigated the left-inguinal non-tumor mammary gland of this mouse, 
which did not accumulate radioiodide above background levels.  Real-time PCR was 
performed using 500 ng of total RNA extracted from each mammary gland to record 
levels of NIS and β-actin mRNA.  The mean Ct values for each gene were converted into 
transcript copy number.  Data are presented as a ratio of NIS: β-actin transcript copy 
number (D).  Amounts of radioiodide uptake and NIS: β-actin transcripts correlate 
between each of these non-tumor mammary glands.  A comparison of NIS: β-actin 
transcripts between the large tumor and the non-palpable tumor of mouse 258 was 
conducted (E).  This graph shows a significant increase in NIS: β-actin ratio in a 
developing tumor compared with an older tumor which has already accumulated iodide.   
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Figure 9.  RT-PCR for NIS mRNA expression in mammary glands of C57 mice. 
 
RT-PCR products from whole mammary glands of a (A) nulliparous mouse (mouse 255) 
right axillary mammary gland, (B) previously pregnant mouse (mouse 250) right inguinal 
mammary gland and (C) lactating mouse (mouse 253) left axillary mammary gland were 
separated on 1.2% agarose gels.  NIS expression is demonstrated by a band of 201 base 
pairs in lane 2 of each gel, as determined by comparison with 1Kb+ DNA ladder in lane 
1.  Lane 3 shows no RT negative controls for NIS in each RT-PCR reaction.  β-actin was 
run in parallel as an internal control (not shown).  
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Figure 10. Comparison of radioiodide uptake and NIS mRNA level in C57 mouse 
mammary glands.   
 
C57 mice were used in this comparative study to compare levels of NIS in MMTV mice 
with C57 mice.  Lactating mice (mouse 251 and mouse 253) were imaged with the 
gamma camera and revealed radioiodide uptake in each mammary gland. The right 
axillary mammary gland of mouse 251 (A) was used for real-time RT-PCR analysis, and 
the left axillary mammary gland was used from mouse 253 (B), each marked with a red 
box.  A multiparous mouse (mouse 250) which had previously been pregnant as well as a 
nulliparous mouse (mouse 255).  Neither mouse exhibited radioiodide uptake in 
mammary gland regions (C and D).  The right inguinal (RI) mammary gland of the 
multiparous mouse (mouse 250) and the right axillary (RA) mammary gland of the 
nulliparous mouse (mouse 255) were removed and analyzed using real-time RT-PCR 
Real-time RT-PCR was performed using 500 ng of total RNA extracted from each tumor 
piece to record levels of NIS and β-actin mRNA.  The mean Ct values for each gene were 
converted into transcript copy number.  Data are presented as a ratio of NIS: β-actin 
transcript copy number (E).  Lactating mammary glands display more mRNA expression 
than multiparous or nulliparous mammary glands.  Mouse 253 exhibited a large increase 
in NIS mRNA level, while mouse 251 showed a more modest increase over non-lactating 
glands.      
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DISCUSSION AND FUTURE DIRECTIONS 
Summary of Conclusions from Results 
 The goal of this research was to determine if a correlation existed between NIS 
mRNA levels and radioiodide uptake in MMTV-induced mouse mammary tumors and 
non-tumor mammary glands.  We hypothesized that NIS function in mammary tumors 
and non-tumor mammary glands is regulated primarily at the transcriptional level.  We 
predicted that tumors or regions of tumors with high levels of radioiodide uptake would 
have correspondingly high levels of NIS mRNA.  Previous studies of in vivo mouse 
models examining radioiodide uptake as mediated through NIS have shown a positive 
correlation between the NIS expression and radioiodide uptake (Kogai, 2004; Dwyer, 
2005).  However, these studies do not directly correlate amounts or patterns of 
radioiodide uptake with NIS mRNA quantification using real-time RT-PCR.   These 
studies also rely on NIS expression driven by a MUC-1 promoter (Dwyer, 2005) or 
induced with trans-retinoic acid (tRA) treatment (Kogai, 2004) rather than endogenous 
NIS expression.  Dwyer et al. (2005) demonstrated NIS protein expression with 
immunohistochemical staining prior to implantation of T47D breast cancer cells, but did 
not correlate radioiodide uptake with any quantitative measurement of NIS expression.  
Kogai et al. (2004) examined NIS expression and radioiodide uptake in a MMTV-PyVT 
breast cancer mouse model following treatment with tRA.  tRA treatments led to 
increases in NIS mRNA levels as measured by quantifying the density of RT-PCR 
product on agarose gels.  A positive correlation between increases in both expression of 
NIS mRNA and radioiodide uptake was observed following treatment with tRA, 
suggesting that NIS function is regulated at the mRNA level.   
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The conclusions from our research suggest that there is tentative for support for 
this hypothesis and previous findings in other model systems, but some contradicting 
results occurred.  First, contradictory results were found in correlating increased NIS 
mRNA expression with increased radioiodide uptake.  In cases such as mouse 229, an 
increase in NIS mRNA directly correlated with an increase in radioiodide uptake.  In 
cases such as mouse 240, no relationship was discovered.  However, there were also 
variations in the patterns of radioiodide uptake and morphology of the tumor, which may 
account for some of the lack of correlation.  Second, higher NIS mRNA levels in non-
tumor mammary glands was significantly correlated with increased radioiodide uptake, 
suggesting that NIS is regulated at the transcriptional level in early tumor development.     
 Whether NIS mRNA levels correlated with radioiodide uptake seemed related to 
variations in the pattern of radioiodide uptake in mammary tumors.  Tumors displaying a 
center-to-edge pattern of uptake (mouse 209 and mouse 229) possessed a positive 
correlation between increased NIS mRNA and increased radioiodide uptake, while 
tumors with a multi-spot pattern of radioiodide uptake (mouse 240) did not show this 
correlation.  Our ROI analysis data suggest that tumors accumulating radioiodide in a 
center-to-edge pattern are younger than those exhibiting a multi-spot pattern.  This 
presents the possibility that as tumors age there is an altered iodide metabolism involving 
NIS mRNA regulation changes as well.  NIS expression and iodide uptake capability has 
been shown by other to be downregulated in this manner during thyroid cancer 
(Schlumberger, 2007), which supports the possibility that a similar change in expression 
and uptake occurs in breast cancer progression.  Additionally, the variable morphology of 
tumors and tumor pieces appeared to relate to whether NIS mRNA and radioiodide 
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uptake positively correlated.  Regions of dense, white tissue more often exhibit a strong 
correlation between NIS mRNA and radioiodide uptake than regions of tumor containing 
blood-filled, necrotic tissue.  
  
NIS mRNA Upregulation during Early Tumor Development  
Mammary glands without palpable tumors (mouse 256, mouse 258, mouse 262) 
showed an increase in NIS mRNA that was positively correlated with an increase in 
radioiodide uptake.  From this finding, we propose that NIS upregulation in early tumor 
development can be effectively imaged using the gamma camera at a stage in which the 
tumor is non-palpable.  Zuckier et al. (2001) and Tazebay et al. (2000) report that 
mammary gland NIS is upregulated in proliferating breast tissue.  In our MMTV mouse, 
spontaneously mammary tumor formation and proliferation appears to trigger this NIS 
upregulation.  Because of the correlation between NIS mRNA and radioiodide uptake in 
these tissues, we can image the presence of proliferating mammary tissue using 
radioiodide.  Additionally, the high resolution of the small animal gamma camera further 
augments the capacity for NIS to serve as a reporter gene for early detection of breast 
cancer (Dingli, 2003).  The measurement of increases in endogenous NIS mRNA as a 
reporter gene combined with the potential to image non-palpable tumors using the 
gamma camera presents a method of early breast cancer detection which surpasses the 
resolution of currently available gamma cameras (Dingli, 2003), while maintaining 
specificity for breast cancer tissue. 
 
 
 71 
Differential Regulation of NIS Expression and Function in Breast Cancer 
 Our studies included both tumors which showed correlation between NIS mRNA 
and functional iodide uptake and tumors which showed no correlation.  This finding 
suggests that NIS can be regulated on the transcriptional level as well as translational 
and/or post-translational levels in breast cancer tissue.  The exact molecular mechanism 
of NIS induction and activation has yet to be described, however (Arturi, 2005).  Studies 
have indicated multiple levels of NIS regulation, but these are limited to in vitro 
experiments using the human adenocarcinoma cell line MCF-7 (Dohan, 2006). 
 In our samples in which increased NIS mRNA expression correlated with 
increased radioiodide uptake on gamma camera images, regulation on the transcriptional 
level is suggested.  Multiple factors have been shown to induce NIS mRNA expression in 
vitro.  Hormonal regulation by insulin, IGF-I, and IGF-II plays a role in mammary cell 
proliferation.  Addition of these hormones to MCF-7 cells also caused an increase in NIS 
mRNA and protein in studies by Arturi et al. (2005).  However, Dohan et al. (2006) were 
unable to reproduce these findings in the absence of trans-retinoic acid (tRA).  
Lactogenic hormones also have been suggested to play a role in NIS activation.  
Prolactin, acting through MAPK or PI3K, and oxytocin, acting through PKC and MAPK, 
have each been implicated in NIS signal transduction, but neither pathway has been fully 
characterized in NIS activation in breast cancer (Knostman, 2004).  Knostman et al. 
(2004) also investigated the role of cAMP in NIS activation in breast cancer.  Treating 
cells with cAMP resulted in a significant increase in NIS mRNA and promoter activity, 
but did not result in increased protein expression or functional iodide uptake.  This 
evidence suggests that while cAMP is able to drive NIS protein and functional iodide 
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uptake in thyroid cells, its effects are limited to the transcriptional level in breast cancer.  
Because MCF-7 cells express a low basal level of NIS, factors to increase expression, 
such as tRA, have been the focus of many studies (Kogai, 2004; Kogai 2005; Dohan, 
2006).  Kogai et al. (2004) found that induction of NIS expression in MCF-7 cells 
requires tRA treatment, and in 2005 showed that addition of dexamethasone further 
increases NIS at the transcriptional level. 
 In our MMTV tumors which exhibited no correlation between NIS mRNA 
expression and NIS functional activity by uptake of radioiodide, we suggest that 
regulation occurred at a post-transcriptional level.  Kogai et al. (2004) showed evidence 
for this type of regulation in a time course treatment of MCF-7 cell xenografts with tRA.  
After day 2, xenografts exhibited the maximum level of NIS mRNA expression 
throughout the time course of tRA treatment, while the maximum levels of both protein 
expression and iodide uptake occurred on day 5.  This finding supports our finding of no 
correlation between NIS mRNA and radioiodide uptake in some tumor tissues.  Kogai 
suggests that this lag time may be due to NIS processing.  Mammary gland NIS is known 
to be glycosylated.  NIS is phosphorylated in thyroid cells, but it is unknown if 
phosphorylation of NIS is required for function in breast cancer.  Membrane targeting is 
also thought to play a role in this lag time between NIS mRNA expression and functional 
iodide uptake. 
 In addition to this study by Kogai, other studies have implicated other signaling 
and regulatory mechanisms.  Knostman et al. (2004) showed that PI3K alone can induce 
NIS function, while, cAMP leads only to increases in mRNA.  This finding demonstrates 
the multiple pathways through which NIS is activated in breast cancer.  Also, Dohan, et 
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al. (2006) have shown that in MCF-7 mammary tumor cells, unlike in thyroid cells, 
increased iodide levels do not have the effect to downregulate iodide transport.  This 
finding suggests evidence for a different pathway of negative feedback control in breast 
cancer, if not a complete lack of negative feedback.   
 Regulation of NIS expression and function on the transcriptional and post-
transcriptional levels has been shown in MCF-7 breast cancer cells.  In our experiments, 
we see evidence that supports differential regulation in our MMTV-mouse model.  
Tumors showing a correlation between NIS mRNA expression and radioiodide uptake 
suggest that regulation in these tissues occurs primarily at the transcriptional level.  While 
the tumors that show a lack of correlation between increases in mRNA and increases in 
radioiodide uptake suggest that the processes seen in Kogai et al. (2004), with an initial 
increase in mRNA level is followed by a lag time for post-transcriptional processing 
before NIS protein and iodide uptake are present, are occurring.  In our experience, we 
see evidence for both models with the correlation between real-time RT-PCR, 
immunohistochemical, and gamma camera imaging data.  Clearly there is a need for 
further investigation both in MCF-7 cell lines as well as with animal models to more 
completely understand where NIS regulation occurs in breast cancer. 
 
Future Directions 
 While our results indicate that in MMTV-induced mouse mammary tumors NIS 
mRNA is correlated with increased radioiodide uptake in younger dense tumors, it does 
not seem to be similarly correlated in older more diffuse tumors.  A significantly 
increased sample size of imaged mice with NIS mRNA measured by real-time RT-PCR 
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and more precisely correlated with location within the tumor will be necessary to make 
more definitive conclusions.  
 A method to further examine the upregulation of NIS mRNA in developing 
mammary tumors should include imaging and real-time RT-PCR on MMTV-infected 
mice which lack tumors.  NIS expression compared with radioiodide uptake in each 
mammary gland should be measured in mice at ages in which the probability of 
developing a tumor is high.   
 In order to more completely understand the regulation of NIS expression in our 
MMTV-model, we should investigate expression patterns of genes which are key 
regulators of NIS function.  Such genes would include ER, and PRL-R.  These studies 
should be performed at the level of mRNA, protein, and function through real-time RT-
PCR, immunohistochemistry, and gamma camera imaging, respectively.  Once 
correlative relationships between NIS and proteins which have a key role in its regulation 
are found in MMTV-mice, the study could continue in primary cultures of MMTV-cells, 
which have already been established.  In these studies, we can perform 
immunocytochemistry should be used to determine the percentage of cells which express 
both NIS and those proteins which regulate its function. 
 To determine more precisely the signaling pathway that regulates NIS mRNA 
expression in our MMTV model, we should employ real-time RT-PCR on primary cell 
cultures following treatments with inhibitors for suspected signaling pathways.  First, 
basal NIS expression should be quantified as transcripts per cell.  Second, treatments with 
inhibitors known to block the function of implicated signaling pathways, such as through 
cAMP and PI3K, should be used in treatments of cells to determine if blocking these 
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pathways decreases amount of NIS mRNA.  Finally, if one or multiple pathways are 
implicated in affecting regulation of NIS mRNA, radioiodide uptake in these cells can be 
measured to determine if the alteration of these pathways prevents functional iodide 
uptake as well. 
 In addition to experiments which investigate the question of NIS regulation in our 
MMTV model, we are interested in the potential of NIS as a marker gene for breast 
cancer.  Using microarray with pre-designed breast cancer gene chips and real-time RT-
PCR, we will investigate what cancer genes are overexpressed in conjunction with NIS.  
While NIS has shown to be an effective imaging reporter gene (Dingli, 2003), we aim to 
evaluate its potential as a marker gene for a more specific gene expression profile.  This 
investigation will contribute not only to our understanding of genes which are co-
expressed with NIS, but will also indicate a potential to use gamma camera imaging with 
radioiodide for molecular imaging that can provide a profile of global gene expression 
within a tumor. 
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APPENDIX 
Real-time RT-PCR Data Plots 
Mouse 240-3 and 209-1 
Current Date:  02-Apr-08 02:12 PM 
Data generated on: 02-Apr-08 at 09:46 AM. 
 
Optical data file name: Data 02-Apr-08 0946.opd 
Plate Setup file used: sassamples.pts 
Protocol file used: sasnisprobes.tmo 
 
PCR Amp/Cycle Graph for FAM-490  
 
Data Analysis Parameters 
 
Calculated threshold using the maximum curvature approach is 22.5. 
Per-well baseline cycles have been determined automatically.   
Data analysis window is set at 95.00% of a cycle, centered at end of the cycle. 
Weighted Mean digital filtering has been applied. Global filtering is off. 
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PCR Quantification Spreadsheet Data for FAM-490  
 
Well Identifier Ct Setpoint 
  
B02 240n1 29.9  
B03 209n1 28.1  
C02 240n2 27.9  
C03 209n2 28.8  
D02 240a1 13.5  
D03 209a1 13.7  
E02 240a2 13.3  
E03 209a2 14  
F02 240n noRT 36.1  
F03 209n noRT 32.8  
G02 240a noRT 35.7  
G03 209a noRT 33.7  
 
 
Mouse 168, 240-1 and 240-2 
Current Date:  02-Apr-08 08:42 PM 
Data generated on: 02-Apr-08 at 06:16 PM. 
 
Optical data file name: Data 02-Apr-08 1815.opd 
Plate Setup file used: sassamples.pts 
Protocol file used: sasnisprobes.tmo 
 
PCR Amp/Cycle Graph for FAM-490  
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Data Analysis Parameters 
 
Calculated threshold using the maximum curvature approach is 25.5. 
Per-well baseline cycles have been determined automatically.   
Data analysis window is set at 95.00% of a cycle, centered at end of the cycle. 
Weighted Mean digital filtering has been applied. Global filtering is off. 
 
PCR Quantification Spreadsheet Data for FAM-490  
 
Well Identifier Ct Setpoint 
  
B01 168n1 27.1  
B02 2401n1 N/A  
B03 2402n1 34.4  
C01 168n2 29.8  
C02 2401n2 30  
C03 2402n2 29.3  
D01 168a1 13.2  
D02 2401a1 13  
D03 2402a1 14.3  
E01 168a2 12.7  
E02 2401a2 13.1  
E03 2402a2 14.1  
F01 168n noRT 31  
F02 2401n noRT 31.3  
F03 2402n noRT 30.7  
G01 168a noRT 31.2  
G02 2401a noRT 28.3  
G03 24029a noRT 30.8  
 
Mouse 209-2, 209-3, and 209-4 
Current Date:  05-Apr-08 03:57 PM 
Data generated on: 05-Apr-08 at 01:29 PM. 
 
Optical data file name: Data 05-Apr-08 1328.opd 
Plate Setup file used: sassamples.pts 
Protocol file used: sasnisprobes.tmo 
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PCR Amp/Cycle Graph for FAM-490  
 
Data Analysis Parameters 
 
Calculated threshold using the maximum curvature approach is 32.9. 
Per-well baseline cycles have been determined automatically.   
Data analysis window is set at 95.00% of a cycle, centered at end of the cycle. 
Weighted Mean digital filtering has been applied. Global filtering is off. 
 
PCR Quantification Spreadsheet Data for FAM-490  
 
Well Identifier Ct Setpoint 
  
B01 2n1 28.7  
B02 3n1 25.6  
B03 4n1 26.7  
C01 2n2 28.7  
C02 3n2 25.5  
C03 4n2 26.6  
D01 2a1 18.6  
D02 3a1 13.6  
D03 4a1 14.3  
E01 2a2 18.6  
E02 3a2 13.6  
E03 4a2 14  
F01 2n noRT 32.5  
F02 3n noRT N/A  
F03 4n noRT 35.1  
G01 2a noRT 33.5  
G02 3a noRT 35.2  
G03 4a noRT 35.6  
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Mouse 240-4, 240-5, and 240-Thyroid 
Current Date:  07-Apr-08 03:15 PM 
Data generated on: 07-Apr-08 at 12:53 PM. 
 
Optical data file name: Data 07-Apr-08 1252.opd 
Plate Setup file used: sassamples.pts 
Protocol file used: sasnisprobes.tmo 
 
PCR Amp/Cycle Graph for FAM-490  
 
Data Analysis Parameters 
 
Calculated threshold using the maximum curvature approach is 28.3. 
Per-well baseline cycles have been determined automatically.   
Data analysis window is set at 95.00% of a cycle, centered at end of the cycle. 
Weighted Mean digital filtering has been applied. Global filtering is off. 
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PCR Quantification Spreadsheet Data for FAM-490  
 
Well Identifier Ct Setpoint 
  
B01 2404n1 N/A  
B02 2405n1 28.3  
B03 240Tn1 26.7  
C01 2404n2 N/A  
C02 2405n2 28.8  
C03 240Tn2 26.3  
D01 2404a1 13.9  
D02 2405a1 13.8  
D03 240Ta1 17.9  
E01 2404a2 13.9  
E02 2405a2 13.8  
E03 240Ta2 31.3  
F01 2404n noRT 28.8  
F02 2405n noRT 31.8  
F03 240Tn noRT 31.2  
G01 2404a noRT 32.7  
G02 2405a noRT 31.8  
G03 240Ta noRT 32.5  
 
Mouse 256, 258-Tumor, and 258 MG 
Current Date:  09-Apr-08 06:54 PM 
Data generated on: 09-Apr-08 at 03:57 PM. 
 
Optical data file name: Data 09-Apr-08 1557.opd 
Plate Setup file used: sassamples.pts 
Protocol file used: sasnisprobes.tmo 
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PCR Amp/Cycle Graph for FAM-490  
 
Data Analysis Parameters 
 
Calculated threshold using the maximum curvature approach is 25.2. 
Per-well baseline cycles have been determined automatically.   
Data analysis window is set at 95.00% of a cycle, centered at end of the cycle. 
Weighted Mean digital filtering has been applied. Global filtering is off. 
 
PCR Quantification Spreadsheet Data for FAM-490  
 
Well Identifier Ct Setpoint 
  
B01 256Mn1 28.2  
B02 258Tn1 29.6  
B03 258Mn1 33.7  
C01 256Mn2 28.8  
C02 258Tn2 29.3  
C03 258Mn2 28.6  
D01 256Ma1 14.7  
D02 258Ta1 13.9  
D03 258Ma1 19  
E01 256Ma2 14.6  
E02 258Ta2 14.2  
E03 258Ma2 19.1  
F01 256Mn noRT 32.8  
F02 258Tn noRT 32.9  
F03 258Mn noRT 29.9  
G01 256Ma noRT 30.6  
G02 258Ta noRT 32.2  
G03 258Ma noRT 26.7  
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Mouse 251, 253, and 262 
Current Date:  11-Apr-08 01:03 AM 
Data generated on: 10-Apr-08 at 11:35 PM. 
 
Optical data file name: Data 10-Apr-08 2335.opd 
Plate Setup file used: sassamples.pts 
Protocol file used: sasnisprobes.tmo 
 
PCR Amp/Cycle Graph for FAM-490  
 
Data Analysis Parameters 
 
Calculated threshold using the maximum curvature approach is 26.6. 
Per-well baseline cycles have been determined automatically.   
Data analysis window is set at 95.00% of a cycle, centered at end of the cycle. 
Weighted Mean digital filtering has been applied. Global filtering is off. 
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PCR Quantification Spreadsheet Data for FAM-490  
 
Well Identifier Ct Setpoint 
  
B01 251n1 31.5  
B02 253n1 25.9  
B03 262n1 14.7  
C01 251n2 30.9  
C02 253n2 26.1  
C03 262n2 15  
D01 251a1 16.4  
D02 253a1 17  
D03 262a1 28.8  
E01 251a2 16.4  
E02 253a2 16.5  
E03 262a2 30  
F01 251n noRT 34.1  
F02 253n noRT 35.9  
F03 262n noRT 34.6  
G01 251a noRT 33.2  
G02 253a noRT 30.7  
G03 262a noRT 29.8  
 
Mouse 209-2, 258MG, 251, and 240-4 
Current Date:  14-Apr-08 02:37 PM 
Data generated on: 14-Apr-08 at 12:34 PM. 
 
Optical data file name: Data 14-Apr-08 1233.opd 
Plate Setup file used: sassamples2.pts 
Protocol file used: sasnisprobes.tmo 
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PCR Amp/Cycle Graph for FAM-490  
 
Data Analysis Parameters 
 
Calculated threshold using the maximum curvature approach is 21.9. 
Per-well baseline cycles have been determined automatically.   
Data analysis window is set at 95.00% of a cycle, centered at end of the cycle. 
Weighted Mean digital filtering has been applied. Global filtering is off. 
 
PCR Quantification Spreadsheet Data for FAM-490  
 
Well Identifier Ct Setpoint 
  
B01 209n1 27.1  
B02 258n1 28.4  
B03 240n 37.6  
C01 209n2 27.5  
C02 258n2 28.1  
C03 240a 12.8  
D01 209a1 13.4  
D02 258a1 14.6  
D03 251n 25.8  
E01 209a2 13.1  
E02 258a2 14.6  
E03 251a 15  
F01 209n noRT 36.8  
F02 258n noRT 36.4  
F03 240n noRT N/A  
G01 209a noRT 29.7  
G02 258a noRT 29.7  
G03 240a noRT 28.7  
H02 251n noRT 37.3  
H03 251a noRT 30.2  
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Mouse 209-2, 251, and 240-4 
Current Date:  15-Apr-08 06:27 PM 
Data generated on: 14-Apr-08 at 05:10 PM. 
 
Optical data file name: Data 14-Apr-08 1709.opd 
Plate Setup file used: sassamples2.pts 
Protocol file used: sasnisprobes.tmo 
 
PCR Amp/Cycle Graph for FAM-490  
 
Data Analysis Parameters 
 
Calculated threshold using the maximum curvature approach is 37.7. 
Per-well baseline cycles have been determined automatically.   
Data analysis window is set at 95.00% of a cycle, centered at end of the cycle. 
Weighted Mean digital filtering has been applied. Global filtering is off. 
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PCR Quantification Spreadsheet Data for FAM-490  
 
Well Identifier Ct Setpoint 
  
C01 209n 27  
C02 240n 35.1  
C03 251n 26.2  
D01 209a 14.1  
D02 240a 14  
D03 251a 15.7  
E01 209n no rt 37.5  
E02 240n no rt 36.3  
E03 251n no rt 37.1  
F01 209a noRT 32.6  
F02 240a noRT 32.6  
F03 251a noRT 33.3  
 
Mouse 250, 255, 261, and 240-Liver 
Current Date:  15-Apr-08 09:56 PM 
Data generated on: 15-Apr-08 at 08:20 PM. 
 
Optical data file name: Data 15-Apr-08 2020.opd 
Plate Setup file used: sassamples3.pts 
Protocol file used: sasnisprobes.tmo 
 
PCR Amp/Cycle Graph for FAM-490  
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Data Analysis Parameters 
 
Calculated threshold using the maximum curvature approach is 28.7. 
Per-well baseline cycles have been determined automatically.   
Data analysis window is set at 95.00% of a cycle, centered at end of the cycle. 
Weighted Mean digital filtering has been applied. Global filtering is off. 
 
PCR Quantification Spreadsheet Data for FAM-490  
 
Well Identifier Ct Setpoint 
  
B01 250n1 27.9  
B02 255n 28.2  
B03 liv n N/A  
C01 250n2 28  
C02 255a 16.4  
C03 liv a 16.1  
D01 250a 15.1  
D02 261n N/A  
D03 liv n no rt 32.7  
E01 250n no rt 32  
E02 261a 13.7  
E03 liv a no rt 32  
F01 250a no rt 31  
F02 261n no rt 33.6  
F03 255n no rt 33.8  
G02 261a no rt 32.1  
G03 255a no rt 30.1  
 
Mouse 229, 251, 258Tumor 
Current Date:  16-Apr-08 07:00 PM 
Data generated on: 16-Apr-08 at 04:50 PM. 
 
Optical data file name: Data 16-Apr-08 1650.opd 
Plate Setup file used: sassamples2.pts 
Protocol file used: sasnisprobes.tmo 
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PCR Amp/Cycle Graph for FAM-490  
 
Data Analysis Parameters 
 
Calculated threshold using the maximum curvature approach is 28.9. 
Per-well baseline cycles have been determined automatically.   
Data analysis window is set at 95.00% of a cycle, centered at end of the cycle. 
Weighted Mean digital filtering has been applied. Global filtering is off. 
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PCR Quantification Spreadsheet Data for FAM-490  
 
Well Identifier Ct Setpoint 
  
B01 T1A n1 27.9  
B02 T1B n 28.5  
B03 T2A n 29  
B04 T2B n 30.1  
B05 T3A n 32.8  
B06 T3B n 31  
C01 T1A n2 28.4  
C02 T1B a 13.9  
C03 T2A a 13.9  
C04 T2B a 13.9  
C05 T3A a 13.6  
C06 T3B a 13.2  
D01 T1A a 13.6  
D02 T1B n no rt 32.2  
D03 T2A n no RT 32.8  
D04 T2B n no RT 32.5  
D05 T3A n no RT 31.8  
D06 T3B n no RT 30.9  
E01 T1A n no rt 33.4  
E02 T1B a no RT 25.6  
E03 T2A a no rt 31  
E04 T2B a no RT 31.7  
E05 T3A a no RT 31.9  
E06 T3B a no RT 31.5  
F01 T1A a no rt 30.8  
F02 251n1 25.2  
F03 251n noRT 33  
F04 258n 30.4  
F05 258n no RT 31.7  
G01 251a 15.2  
G02 251n2 25.1  
G03 251a no rt 31.5  
G04 258a 14  
G05 258 a no rt 31.6  
 
 
 
